<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ABSTRAL- fentanyl citrate tablet </strong><br>Galena Biopharma, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use ABSTRAL safely and effectively. See full prescribing information for ABSTRAL. <br>ABSTRAL<span class="Sup">®</span> (fentanyl) sublingual tablets CII  <br>Initial U.S. Approval: 1968
</div>
<div class="Warning">
<div>
<h1 class="Warning">
<span class="Bold">WARNING: RISK OF <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">RESPIRATORY DEPRESSION</span>,</span><br><span class="Bold">MEDICATION ERRORS, ABUSE POTENTIAL</span>
</h1>
<h1 class="Warning"><span class="Bold Italics">See full prescribing information for complete boxed warning.</span></h1>
<ul class="Disc">
<li><span class="Bold">Due to the risk of fatal <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, ABSTRAL is contraindicated in opioid non-tolerant patients (<a href="#s6">1</a>) and in management of acute or <span class="product-label-link" type="condition" conceptid="439502" conceptname="Postoperative pain">postoperative pain</span>, including <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>/<span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraines</span>. (<a href="#s16">4</a>)</span></li>
<li><span class="Bold">Keep out of reach of children. (<a href="#s20">5.3</a>)</span></li>
<li><span class="Bold">Use with CYP3A4 inhibitors may cause fatal <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>.</span></li>
<li><span class="Bold">(<a href="#s30">7</a>)</span></li>
<li><span class="Bold">When prescribing, do not convert patients on a mcg per mcg basis from any other oral transmucosal fentanyl product to ABSTRAL. (<a href="#s8">2.1</a>, <a href="#s19">5.2</a>)</span></li>
<li><span class="Bold">When dispensing, do not substitute with any other fentanyl products. (<a href="#s19">5.2</a>)</span></li>
<li><span class="Bold">Contains fentanyl, a Schedule II controlled substance with abuse liability similar to other opioid analgesics. (<a href="#s40">9.1</a>)</span></li>
<li><span class="Bold">ABSTRAL is available only through a restricted program called the TIRF REMS Access program. Outpatients, healthcare professionals who prescribe to outpatients, pharmacies, and distributors are required to enroll in the program. (<a href="#s27">5.10</a>)</span></li>
</ul>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div><p class="Highlighta">Dosage and Administration, Conversion from Actiq (<a href="#s10">2.2</a>)            11/2014
 </p></div>
</div>
<div></div>
<div class="Warning">
<div>
<h1 class="Warning">
<span class="Bold">WARNING: RISK OF <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">RESPIRATORY DEPRESSION</span>,</span><br><span class="Bold">MEDICATION ERRORS, ABUSE POTENTIAL</span>
</h1>
<h1 class="Warning"><span class="Bold Italics">See full prescribing information for complete boxed warning.</span></h1>
<ul class="Disc">
<li><span class="Bold">Due to the risk of fatal <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, ABSTRAL is contraindicated in opioid non-tolerant patients (<a href="#s6">1</a>) and in management of acute or <span class="product-label-link" type="condition" conceptid="439502" conceptname="Postoperative pain">postoperative pain</span>, including <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>/<span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraines</span>. (<a href="#s16">4</a>)</span></li>
<li><span class="Bold">Keep out of reach of children. (<a href="#s20">5.3</a>)</span></li>
<li><span class="Bold">Use with CYP3A4 inhibitors may cause fatal <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>.</span></li>
<li><span class="Bold">(<a href="#s30">7</a>)</span></li>
<li><span class="Bold">When prescribing, do not convert patients on a mcg per mcg basis from any other oral transmucosal fentanyl product to ABSTRAL. (<a href="#s8">2.1</a>, <a href="#s19">5.2</a>)</span></li>
<li><span class="Bold">When dispensing, do not substitute with any other fentanyl products. (<a href="#s19">5.2</a>)</span></li>
<li><span class="Bold">Contains fentanyl, a Schedule II controlled substance with abuse liability similar to other opioid analgesics. (<a href="#s40">9.1</a>)</span></li>
<li><span class="Bold">ABSTRAL is available only through a restricted program called the TIRF REMS Access program. Outpatients, healthcare professionals who prescribe to outpatients, pharmacies, and distributors are required to enroll in the program. (<a href="#s27">5.10</a>)</span></li>
</ul>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">ABSTRAL is an opioid agonist indicated for the management of breakthrough <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in cancer patients 18 years of age and older who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>. (<a href="#s6">1</a>) Limitations of Use:
 </p>
<p class="Highlighta">ABSTRAL may be dispensed only to patients enrolled in the TIRF REMS Access program.
 </p>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul class="Disc">
<li>Patients must require and use around-the-clock opioids when taking ABSTRAL (<a href="#s6">1</a>)
</li>
<li>Initial dose of ABSTRAL: 100 mcg. (<a href="#s8">2.1</a>)
</li>
<li>Individually titrate to a tolerable dose that provides adequate <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span>. (<a href="#s8">2.1</a>)
</li>
<li>No more than two doses can be taken per breakthrough <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> episode. (<a href="#s8">2.1</a>)
</li>
<li>Wait at least 2 hours before treating another episode of breakthrough <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>
</li>
<li>with ABSTRAL. (<a href="#s8">2.1</a>)
</li>
<li>Limit consumption to treat four or fewer breakthrough <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> episodes per day once a successful dose is found. (<a href="#s12">2.4</a>)
</li>
<li>Administer on the floor of the mouth directly under the tongue and allow to completely dissolve. (<a href="#s13">2.5</a>)
</li>
</ul></div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><ul class="Disc"><li>Sublingual tablet in 100 mcg, 200 mcg, 300 mcg, 400 mcg, 600 mcg and 800 mcg strengths. (<a href="#s15">3</a>)
</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul class="Disc">
<li>Opioid non-tolerant patients. (<a href="#s16">4</a>)
</li>
<li>Management of acute or <span class="product-label-link" type="condition" conceptid="439502" conceptname="Postoperative pain">postoperative pain</span> including <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>/<span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraines</span> dental <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>. (<a href="#s16">4</a>)
</li>
<li>Intolerance or <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to fentanyl or components of ABSTRAL. (<a href="#s16">4</a>)
</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disc">
<li>Clinically significant respiratory and <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS depression</span> can occur. Monitor patients accordingly. (<a href="#s18">5.1</a>, <a href="#s21">5.4</a>)
</li>
<li>Do not convert patients on a mcg per mcg basis from another fentanyl product to ABSTRAL. (<a href="#s19">5.2</a>)
</li>
<li>ABSTRAL contains fentanyl in a dose that can be fatal to a child. Ensure proper storage and disposal. (<a href="#s20">5.3</a>, <a href="#s68">16.3</a>)
</li>
<li>Use with other CNS depressants and potent cytochrome P450 3A4 inhibitors may increase depressant effects including <span class="product-label-link" type="condition" conceptid="312603" conceptname="Hypoventilation">hypoventilation</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, and profound sedation. Consider dosage adjustments if warranted. (<a href="#s21">5.4</a>, <a href="#s30">7</a>)
</li>
<li>Titrate ABSTRAL cautiously in patients with <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">chronic obstructive pulmonary disease</span> or pre-existing medical conditions predisposing them to <span class="product-label-link" type="condition" conceptid="312603" conceptname="Hypoventilation">hypoventilation</span>, and in patients susceptible to intracranial effects of CO<span class="Sub">2</span> retention. (<a href="#s23">5.6</a>, <a href="#s24">5.7</a>)
</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<ul class="Disc"><li>Most common (total frequency ≥ 3%): <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, and <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>. (<a href="#s29">6.1</a>)
</li></ul>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Galena Biopharma, Inc.  at 1-888-227-8725 or FDA at 1-800-FDA-1088 or </span><span class="Bold Italics">www.fda.gov/ medwatch</span><span class="Bold">.</span> </p>
</div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul class="Disc"><li>See <a href="#s2">Boxed Warning</a> and Warnings and Precautions (<a href="#s17">5</a>)
</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul class="Disc"><li>Administer ABSTRAL with caution to patients with renal or hepatic dysfunction. (<a href="#s37">8.6</a>)
</li></ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
</div>
<div><div></div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.</p>
<p class="HighlightsRevision">Revised: 11/2014</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">WARNING: RISK OF <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">RESPIRATORY DEPRESSION</span>, MEDICATION ERRORS, ABUSE POTENTIAL
</a></h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE
</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION
</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Dose Titration
</a></h2>
<h2><a href="#section-2.2" class="toc"><span class="XmChange"></span>2.2  Conversion from Actiq
</a></h2>
<h2><a href="#section-2.3" class="toc">2.3 Maintenance Therapy
</a></h2>
<h2><a href="#section-2.4" class="toc">2.4 Dose Re-adjustment
</a></h2>
<h2><a href="#section-2.5" class="toc">2.5 Administration of ABSTRAL
</a></h2>
<h2><a href="#section-2.6" class="toc">2.6 Discontinuation of Therapy
</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS
</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS
</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS
</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 <span class="product-label-link" type="condition" conceptid="312603" conceptname="Hypoventilation">Hypoventilation</span> (<span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory Depression</span>)
</a></h2>
<h2><a href="#section-5.2" class="toc">5.2 ABSTRAL and Other Fentanyl Products
</a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Patient/Caregiver Instructions
</a></h2>
<h2><a href="#section-5.4" class="toc">5.4 Additive CNS Depressant Effects
</a></h2>
<h2><a href="#section-5.5" class="toc">5.5 Effects on Ability to Drive and Use Machines
</a></h2>
<h2><a href="#section-5.6" class="toc">5.6 Chronic Pulmonary Disease
</a></h2>
<h2><a href="#section-5.7" class="toc">5.7 Head Injuries and <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">Increased Intracranial Pressure</span>
</a></h2>
<h2><a href="#section-5.8" class="toc">5.8 Cardiac Disease
</a></h2>
<h2><a href="#section-5.9" class="toc">5.9 MAO Inhibitors
</a></h2>
<h2><a href="#section-5.10" class="toc">5.10 Transmucosal immediate Release Fentanyl (TIRF) Risk Evaluation and Mitigation Strategy (REMS) Access Program
</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS
</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Studies Experience
</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS
</a></h1>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS
</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy - Category C
</a></h2>
<h2><a href="#section-8.2" class="toc">8.2 Labor and Delivery
</a></h2>
<h2><a href="#section-8.3" class="toc">8.3 Nursing Mothers
</a></h2>
<h2><a href="#section-8.4" class="toc">8.4 Pediatric Use
</a></h2>
<h2><a href="#section-8.5" class="toc">8.5 Geriatric Use
</a></h2>
<h2><a href="#section-8.6" class="toc">8.6 Patients with Renal and <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>
</a></h2>
<h2><a href="#section-8.7" class="toc">8.7 Gender
</a></h2>
<h1><a href="#section-9" class="toc">9 DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span>
</a></h1>
<h2><a href="#section-9.1" class="toc">9.1 Controlled Substance
</a></h2>
<h2><a href="#section-9.2" class="toc">9.2 Abuse and Addiction
</a></h2>
<h2><a href="#section-9.3" class="toc">9.3 <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span>
</a></h2>
<h1><a href="#section-10" class="toc">10 OVERDOSAGE
</a></h1>
<h2><a href="#section-10.1" class="toc">10.1 Clinical Presentation
</a></h2>
<h2><a href="#section-10.2" class="toc">10.2 Immediate Management
</a></h2>
<h2><a href="#section-10.3" class="toc">10.3 Treatment of Overdosage (Accidental Ingestion) in the Opioid NON-Tolerant Person
</a></h2>
<h2><a href="#section-10.4" class="toc">10.4 Treatment of Overdosage in Opioid-Tolerant Patients
</a></h2>
<h2><a href="#section-10.5" class="toc">10.5 General Considerations for <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Overdose</span>
</a></h2>
<h1><a href="#section-11" class="toc">11 DESCRIPTION
</a></h1>
<h1><a href="#section-12" class="toc">12 CLINICAL PHARMACOLOGY
</a></h1>
<h2><a href="#section-12.1" class="toc">12.1 Mechanism of Action
</a></h2>
<h2><a href="#section-12.2" class="toc">12.2 Pharmacodynamics
</a></h2>
<h2><a href="#section-12.3" class="toc">12.3 Pharmacokinetics
</a></h2>
<h1><a href="#section-13" class="toc">13 NONCLINICAL TOXICOLOGY
</a></h1>
<h2><a href="#section-13.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
</a></h2>
<h1><a href="#section-14" class="toc">14 CLINICAL STUDIES
</a></h1>
<h1><a href="#section-15" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING
</a></h1>
<h2><a href="#section-15.1" class="toc">16.1 Storage and Handling
</a></h2>
<h2><a href="#section-15.2" class="toc">16.2 Disposal of ABSTRAL
</a></h2>
<h2><a href="#section-15.3" class="toc">16.3 How Supplied
</a></h2>
<h1><a href="#section-16" class="toc">17 PATIENT COUNSELING INFORMATION
</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="dcl-dpl"></a><a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="s2"></a><a name="section-1"></a><p></p>
<h1>WARNING: RISK OF <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">RESPIRATORY DEPRESSION</span>, MEDICATION ERRORS, ABUSE POTENTIAL
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s3"></a><a name="section-1.1"></a><p></p>
<p class="First"><span class="Bold Underline"><span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">RESPIRATORY DEPRESSION</span></span></p>
<p><span class="Bold">Fatal <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> has occurred in patients treated with immediate-release transmucosal fentanyl, including following use in opioid non-tolerant patients and improper dosing. The substitution of ABSTRAL for any other fentanyl product may result in fatal <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>.</span></p>
<p><span class="Bold">Due to the risk of <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, ABSTRAL is contraindicated in the management of acute or <span class="product-label-link" type="condition" conceptid="439502" conceptname="Postoperative pain">postoperative pain</span> including <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>/<span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> and in opioid non-tolerant patients.
</span><span class="Bold Italics">[see Contraindications (<a href="#s16">4</a>)]</span></p>
<p><span class="Bold">ABSTRAL must be kept out of reach of children.
</span><span class="Bold Italics">[see Patient Counseling Information (17.1) and How Supplied/Storage and Handling (<a href="#s66">16.1</a>)]</span></p>
<p>The concomitant use of ABSTRAL with CYP3A4 inhibitors may result in an increase in fentanyl plasma concentrations, and may cause potentially fatal <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>. <span class="Italics">[see Drug Interactions (<a href="#s30">7</a>)]</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s4"></a><a name="section-1.2"></a><p></p>
<p class="First"><span class="Bold Underline">MEDICATION ERRORS</span></p>
<p><span class="Bold">Substantial differences exist in the pharmacokinetic profile of ABSTRAL compared to other fentanyl products that result in clinically important differences in the extent of absorption of fentanyl that could result in fatal <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>.</span></p>
<dl>
<dt>-
</dt>
<dd><span class="Bold">When prescribing, do not convert patients on a mcg per mcg basis from any other fentanyl products to ABSTRAL. (<a href="#s8">2.1</a>)</span></dd>
<dt>-
</dt>
<dd><span class="Bold">When dispensing, do not substitute an ABSTRAL prescription for other fentanyl products.</span></dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5"></a><a name="section-1.3"></a><p></p>
<p class="First"><span class="Bold Underline">ABUSE POTENTIAL</span></p>
<p><span class="Bold">ABSTRAL contains fentanyl, an opioid agonist and a Schedule II controlled substance, with an abuse liability similar to other opioid analgesics. ABSTRAL can be abused in a manner similar to other opioid agonists, legal or illicit. This should be considered when prescribing or dispensing ABSTRAL in situations where the physician or pharmacist is concerned about an increased risk of misuse, abuse or diversion.</span></p>
<p><span class="Bold">Because of the risk for misuse, abuse, addiction, and <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, ABSTRAL is available only through a restricted program, required by the Food and Drug Administration, called a R</span>isk <span class="Bold">E</span>valuation <span class="Bold">and M</span>itigation <span class="Bold">S</span>trategy <span class="Bold">(REMS).</span> Under the TIRF (<span class="Bold">T</span>ransmucosal <span class="Bold">I</span>mmediate <span class="Bold">R</span>elease <span class="Bold">F</span>entanyl) REMS Access program, outpatients, healthcare professionals who prescribe to outpatients, pharmacies, and distributors must enroll in the program [see <span class="Italics">Warnings and Precautions</span> (<a href="#s27">5.10</a>)]. Further information is available at <span class="Underline">www.TIRFREMSAccess.com</span> or by calling1-866-822-1483.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="s6"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE
</h1>
<p class="First">ABSTRAL (fentanyl) sublingual tablets are indicated for the management of breakthrough <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in cancer patients 18 years of age and older who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>. Patients considered opioid tolerant are those who are taking around-theclock medicine consisting of at least 60 mg of oral morphine daily, or at least 25 mcg of transdermal fentanyl/hour, or at least 30 mg of oral oxycodone daily, or at least 8 mg of oral hydromorphone daily or at least 25 mg oral oxymorphone daily, or an equianalgesic dose of another opioid medication daily for a week or longer. <span class="Underline">Patients must remain on around-the-clock opioids when taking ABSTRAL</span>.
</p>
<p>ABSTRAL is contraindicated for patients who are not already tolerant to opioids because life-threatening <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> could result at any dose in patients not on a chronic regimen of opioids. For this reason, ABSTRAL is contraindicated in the management of acute or <span class="product-label-link" type="condition" conceptid="439502" conceptname="Postoperative pain">postoperative pain</span>, including <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>/<span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>, dental <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, or use in the emergency room.
</p>
<p>ABSTRAL is intended to be prescribed only by healthcare professionals who are knowledgeable of, and skilled in, the use of Schedule II opioids to treat cancer <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>.
</p>
<p>Limitations of Use:
</p>
<p>As a part of the TIRF REMS Access program, ABSTRAL may be dispensed only to outpatients enrolled in the program [see <span class="Italics">Warnings and Precautions</span> (<a href="#s27">5.10</a>)]. For inpatient administration of ABSTRAL (e.g., hospitals, hospices, and long-term care facilities that prescribe for inpatient use), patient and prescriber enrollment is not required.
</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="s7"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION
</h1>
<p class="First">Healthcare professionals who prescribe ABSTRAL on an outpatient basis must enroll in the TIRF REMS
</p>
<p>Access program and comply with the requirements of the REMS to ensure safe use of ABSTRAL [See <span class="Italics">Warnings and Precautions</span> (<a href="#s27">5.10</a>)].
</p>
<p>As with all opioids, the safety of patients using such products is dependent on health care professionals prescribing them in strict conformity with their approved labeling with respect to patient selection, dosing, and proper conditions for use.
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s8"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Dose Titration
</h2>
<p class="First">The objective of dose titration is to identify an effective and tolerable maintenance dose for ongoing management of breakthrough cancer <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> episodes. The effective and tolerable dose of ABSTRAL will be determined by dose titration in individual patients.
</p>
<p>Carefully supervise patients until a dose that provides adequate <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> with tolerable side effects is reached for breakthrough <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> control.
</p>
<p><span class="Underline">Starting Dose</span>: Individually titrate ABSTRAL to a dose that provides adequate <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> with tolerable side effects. Begin titration of <span class="Bold">all</span> patients with an initial dose of ABSTRAL of 100 mcg. Due to differences in the pharmacokinetic properties and individual variability, even patients switching from other fentanyl containing products to ABSTRAL must start with the 100 mcg dose. However, for patients converting from Actiq, see <a href="#t1">Table 1</a>: Initial Dosing Recommendations for Patients on ACTIQ.  ABSTRAL is not equivalent on a mcg per mcg basis with all other fentanyl products, therefore, do not switch patients on a mcg per mcg basis from any other fentanyl product. ABSTRAL is NOT a generic version of any other fentanyl product.
</p>
<p>Start all patients with a single 100 mcg tablet.
</p>
<ul class="Disc">
<li>If adequate <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> is obtained within 30 minutes of administration of the 100 mcg tablet, continue to treat subsequent episodes of breakthrough <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> with this dose.
</li>
<li>If adequate <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> is not obtained after ABSTRAL, the patient may use a second ABSTRAL dose (after 30 minutes) as directed by their health care provider. No more than two doses of ABSTRAL may be used to treat an episode of breakthrough <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>.
</li>
<li>Patients must wait at least 2 hours before treating another episode of breakthrough <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> with ABSTRAL.
</li>
</ul>
<div class="Section" data-sectionCode="42229-5">
<a name="s9"></a><a name="section-2.1.1"></a><p></p>
<p class="First"><span class="Underline">Titration Steps</span>: If adequate <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> was not obtained with the first 100 mcg dose, continue dose escalation in a stepwise manner over consecutive breakthrough episodes until adequate <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> with tolerable side effects is achieved. Increase the dose by 100 mcg multiples up to 400 mcg as needed. If adequate <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> is not obtained with a 400 mcg dose, the next titration step is 600 mcg. If adequate <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> is not obtained with a 600 mcg dose, the next titration step is 800 mcg. During titration, patients can be instructed to use multiples of 100 mcg tablets and/or 200 mcg tablets for any single dose. Instruct patients not to use more than 4 tablets at one time. If adequate <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> is not obtained 30 minutes after the use of ABSTRAL, the patient may repeat the same dose of ABSTRAL. No more than two doses of ABSTRAL may be used to treat an episode of breakthrough <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>. Rescue medication as directed by the health care provider can be used if adequate <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> is not achieved after use of ABSTRAL.
</p>
<p>The efficacy and safety of doses higher than 800 mcg have not been evaluated in clinical studies in patients.
</p>
<p><a name="f01"></a><img alt="Figure
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=f969e2bc-6297-4e29-89d3-a3685a2c7c6b&amp;name=abs02-0001-01.jpg"></p>
<p>In order to minimize the risk of ABSTRAL-related adverse reactions and to identify the appropriate dose, it is imperative that patients be supervised closely by health professionals during the titration process.
</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s10"></a><a name="section-2.2"></a><p></p>
<h2 style="border-left:1px solid;">
<span class="XmChange"></span>2.2  Conversion from Actiq
</h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange"></span>The initial dose of Abstral is always 100 mcg with the only exception being patients already using Actiq.
</p>
<ol class="LittleAlpha">
<li style="border-left:1px solid;">
<span class="XmChange"></span>For patients being converted from Actiq, prescribers must use the Initial Dosing Recommendations for Patients on Actiq.  See <a href="#t1">Table 1</a> for initial dosing recommendations. Patients must be instructed to stop the use of Actiq and dispose of any remaining units.<a name="t1"></a><table width="100%">
<caption><span>Table 1: Initial Dosing Recommendations for Patients on ACTIQ
</span></caption>
<col align="left" width="50.000%">
<col align="left" width="50.000%">
<tbody class="Headless">
<tr class="First"><td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="top">
<span class="XmChange"></span>Current ACTIQ Dose (mcg) Initial Abstral Dose (mcg)
</td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top">
<span class="XmChange"></span>200
</td>
<td class="Botrule Rrule" align="center" valign="top">100 mcg
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top">
<span class="XmChange"></span>400
</td>
<td class="Botrule Rrule" align="center" valign="top">200 mcg
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top">
<span class="XmChange"></span>600
</td>
<td class="Botrule Rrule" align="center" valign="top">200 mcg
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top">
<span class="XmChange"></span>800
</td>
<td class="Botrule Rrule" align="center" valign="top">200 mcg
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top">
<span class="XmChange"></span>1200
</td>
<td class="Botrule Rrule" align="center" valign="top">200 mcg
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="center" valign="top">
<span class="XmChange"></span>1600
</td>
<td class="Botrule Rrule" align="center" valign="top">400 mcg
</td>
</tr>
</tbody>
</table>
</li>
<li style="border-left:1px solid;">
<span class="XmChange"></span>For patients converting from Actiq doses of 200 mcg and 400 mcg, initiate titration with 100 mcg and 200 mcg of Abstral, respectively and proceed using multiples of this strength.
</li>
<li style="border-left:1px solid;">
<span class="XmChange"></span>For patients converting from Actiq doses of 600 and 800 mcg, initiate titration with 200 mcg and 200 mcg Abstral, respectively and proceed using multiples of this strength.
</li>
<li style="border-left:1px solid;">
<span class="XmChange"></span>For patients converting from Actiq doses of 1200 and 1600 mcg, initiate titration with 200 mcg and 400 mcg Abstral, respectively and proceed using multiples of this strength.
</li>
</ol>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s11"></a><a name="section-2.3"></a><p></p>
<h2>2.3 Maintenance Therapy
</h2>
<p class="First">Once an appropriate dose for <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> management has been established, instruct patients to use only one ABSTRAL tablet of the appropriate strength per dose. Maintain patients on this dose.
</p>
<p>If adequate <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> is not obtained after use of ABSTRAL, the patient may use a second ABSTRAL dose (after 30 minutes) as directed by their health care provider. No more than two doses of ABSTRAL may be used to treat an episode of breakthrough <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>.
</p>
<p>Patients must wait at least 2 hours before treating another episode of breakthrough <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> with ABSTRAL.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s12"></a><a name="section-2.4"></a><p></p>
<h2>2.4 Dose Re-adjustment
</h2>
<p class="First">If the response (<span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> or adverse reactions) to the titrated ABSTRAL dose markedly changes, an adjustment of dose may be necessary to ensure that an appropriate dose is maintained.
</p>
<p>If more than four episodes of breakthrough <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> are experienced per day, re-evaluate the dose of the longacting opioid used for persistent underlying cancer <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>. If the long-acting opioid or dose of long-acting opioid is changed, re-evaluate and re-titrate the ABSTRAL dose as necessary to ensure the patient is on an appropriate dose.
</p>
<p>Limit the use of ABSTRAL to treat four or fewer episodes of breakthrough <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> per day.
</p>
<p>It is imperative that any dose re-titration is monitored carefully by a healthcare professional.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s13"></a><a name="section-2.5"></a><p></p>
<h2>2.5 Administration of ABSTRAL
</h2>
<p class="First">Place ABSTRAL tablets on the floor of the mouth directly under the tongue immediately after removal from the <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> unit. Do not chew, suck, or swallow ABSTRAL tablets. Allow ABSTRAL tablets to completely dissolve in the sublingual cavity. Advise patients not to eat or drink anything until the tablet is completely dissolved.
</p>
<p>In patients who have a <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, water may be used to moisten the buccal mucosa <span class="Bold">before</span> taking ABSTRAL.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s14"></a><a name="section-2.6"></a><p></p>
<h2>2.6 Discontinuation of Therapy
</h2>
<p class="First">For patients no longer requiring opioid therapy, consider discontinuing ABSTRAL along with a gradual downward titration of other opioids to minimize possible withdrawal effects.
</p>
<p>In patients who continue to take their chronic opioid therapy for persistent <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> but no longer require treatment for breakthrough <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, ABSTRAL therapy can usually be discontinued immediately.
</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="s15"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS
</h1>
<p class="First">ABSTRAL is formulated as a sublingual tablet and is available in six strengths, distinguishable by the shape of the tablet and by de- bossing on the tablet surface. All tablets are white:
</p>
<p>100 microgram tablet is a round tablet marked with the number "1"
</p>
<p>200 microgram tablet is an oval-shaped tablet marked with the number "2"
</p>
<p>300 microgram tablet is a triangle-shaped tablet marked with the number "3"
</p>
<p>400 microgram tablet is a diamond-shaped tablet marked with the number "4"
</p>
<p>600 microgram tablet is a "D"-shaped tablet marked with the number "6"
</p>
<p>800 microgram tablet is a capsule-shaped tablet marked with the number "8"
</p>
<p>[see <span class="Italics">How Supplied/Storage and Handling</span> (16.4)].
</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="s16"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS
</h1>
<p class="First">ABSTRAL is contraindicated in the management of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in opioid non-tolerant patients, because lifethreatening <span class="product-label-link" type="condition" conceptid="312603" conceptname="Hypoventilation">hypoventilation</span> could occur at any dose in patients not already taking around-the-clock opioid therapy. Patients considered opioid tolerant are those who are taking at least 60 mg oral morphine/day, or at least 25 mcg transdermal fentanyl/hour, 30 mg oral oxycodone/day, 8 mg oral hydromorphone/day, 25 mg oral oxymorphone/day, or an equianalgesic dose of another opioid for a week or longer.
</p>
<p>ABSTRAL is contraindicated in the management of acute or <span class="product-label-link" type="condition" conceptid="439502" conceptname="Postoperative pain">postoperative pain</span>, including <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>/<span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>, dental <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, or use in the emergency room.
</p>
<p>ABSTRAL is contraindicated in patients with known intolerance or <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to any of its components or the drug fentanyl. <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span> and <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> have been reported in association with the use of other oral transmucosal fentanyl products.
</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="s17"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS
</h1>
<p class="First"><span class="Bold">See </span><span class="Bold Italics"><a href="#s2">Boxed Warning</a></span><span class="Bold">- WARNINGS: IMPORTANCE OF PROPER PATIENT SELECTION and POTENTIAL FOR ABUSE</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="s18"></a><a name="section-5.1"></a><p></p>
<h2>5.1 <span class="product-label-link" type="condition" conceptid="312603" conceptname="Hypoventilation">Hypoventilation</span> (<span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory Depression</span>)
</h2>
<p class="First">Serious or fatal <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> can occur even at recommended doses in patients using ABSTRAL. <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory depression</span> is more likely to occur in patients with underlying <span class="product-label-link" type="condition" conceptid="320136" conceptname="Disorder of respiratory system">respiratory disorders</span> and elderly or debilitated patients, usually following large initial doses, including ABSTRAL, in opioid non-tolerant patients, or when opioids are given in conjunction with other drugs that depress respiration.
</p>
<p><span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory depression</span> from opioids is manifested by a reduced urge to breathe and a decreased rate of respiration, often associated with the "sighing" pattern of breathing (deep breaths separated by abnormally long pauses). <span class="product-label-link" type="condition" conceptid="4135927" conceptname="Carbon dioxide">Carbon dioxide</span> retention from opioid- induced <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> can exacerbate the sedating effects of opioids. This makes <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdoses</span> involving drugs with sedative properties and opioids especially dangerous.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s19"></a><a name="section-5.2"></a><p></p>
<h2>5.2 ABSTRAL and Other Fentanyl Products
</h2>
<p class="First">ABSTRAL is NOT equivalent to all other fentanyl products used to treat breakthrough <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> on a mcg per mcg basis. There are differences in the pharmacokinetics of ABSTRAL relative to other fentanyl products which could potentially result in clinically important differences in the amount of fentanyl absorbed and could result in a fatal <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>.
</p>
<p>When prescribing ABSTRAL to a patient, DO NOT convert on a mcg to mcg basis from other fentanyl products. Directions for safely converting patients to ABSTRAL from other fentanyl products are not currently available except for Actiq [see <span class="Italics">Conversion from Actiq</span> (<a href="#s10">2.2</a>) ]. This includes oral, transdermal, or parenteral formulations of fentanyl. Therefore, for opioid-tolerant patients starting treatment for breakthrough <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, the initial dose of ABSTRAL is 100 mcg. Individually titrate each patient's dose to provide adequate <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> while minimizing side effects. [See <span class="Italics">Dosage and Administration</span> (<a href="#s8">2.1</a>)]
</p>
<p>When dispensing ABSTRAL to a patient, DO NOT substitute it for any other fentanyl product prescription.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s20"></a><a name="section-5.3"></a><p></p>
<h2>5.3 Patient/Caregiver Instructions
</h2>
<p class="First"><span class="Bold">Patients and their caregivers must be instructed that ABSTRAL contains a medicine in an amount which can be fatal to a child.</span> Even though ABSTRAL is provided in child-resistant packaging, patients and their caregivers must be instructed to keep tablets out of the reach of children. [see <span class="Italics">How Supplied/Storage and Handling</span> (<a href="#s66">16.1</a>, <a href="#s67">16.2</a>), and <span class="Italics">Patient Counseling Information</span> (17.1, 17.2)].
</p>
<p><span class="Bold">Taking ABSTRAL could be fatal in individuals for whom it is not prescribed and for those who are not opioid-tolerant.</span></p>
<p>Physicians and dispensing pharmacists must specifically question patients or caregivers about the presence of children in the home (on a full time or visiting basis) and counsel them regarding the dangers to children from inadvertent exposure.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s21"></a><a name="section-5.4"></a><p></p>
<h2>5.4 Additive CNS Depressant Effects
</h2>
<p class="First">The concomitant use of ABSTRAL with other CNS depressants, including other opioids, sedatives or hypnotics, general anesthetics, phenothiazines, tranquilizers, skeletal muscle relaxants, sedating antihistamines, and alcoholic beverages may produce increased depressant effects (e.g., <span class="product-label-link" type="condition" conceptid="312603" conceptname="Hypoventilation">hypoventilation</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, and profound sedation). Concomitant use with potent inhibitors of cytochrome P450 3A4 isoform (e.g., erythromycin, ketoconazole, and certain protease inhibitors) may increase fentanyl levels, resulting in increased depressant effects [see <span class="Italics">Drug Interactions</span> (<a href="#s30">7</a>)].
</p>
<p>Patients on concomitant CNS depressants must be monitored for a change in opioid effects and the dose of ABSTRAL adjusted, if warranted.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s22"></a><a name="section-5.5"></a><p></p>
<h2>5.5 Effects on Ability to Drive and Use Machines
</h2>
<p class="First">Opioid analgesics impair the mental and/or physical ability required for the performance of potentially dangerous tasks (e.g., driving a car or operating machinery). Warn patients taking ABSTRAL of these dangers and counsel them accordingly.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s23"></a><a name="section-5.6"></a><p></p>
<h2>5.6 Chronic Pulmonary Disease
</h2>
<p class="First">Because potent opioids can cause <span class="product-label-link" type="condition" conceptid="312603" conceptname="Hypoventilation">hypoventilation</span>, titrate ABSTRAL with caution in patients with <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">chronic obstructive pulmonary disease</span> or pre-existing medical conditions predisposing them to <span class="product-label-link" type="condition" conceptid="312603" conceptname="Hypoventilation">hypoventilation</span>. In such patients, even normal therapeutic doses of ABSTRAL may further decrease respiratory drive to the point of <span class="product-label-link" type="condition" conceptid="4256228" conceptname="Respiratory failure">respiratory failure</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s24"></a><a name="section-5.7"></a><p></p>
<h2>5.7 Head Injuries and <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">Increased Intracranial Pressure</span>
</h2>
<p class="First">Administer ABSTRAL with extreme caution in patients who may be particularly susceptible to the intracranial effects of CO<span class="Sub">2</span> retention such as those with evidence of <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">increased intracranial pressure</span> or impaired consciousness. Opioids may obscure the clinical course of a patient with a <span class="product-label-link" type="condition" conceptid="375415" conceptname="Injury of head">head injury</span>; use only if clinically warranted.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s25"></a><a name="section-5.8"></a><p></p>
<h2>5.8 Cardiac Disease
</h2>
<p class="First">Intravenous administration of fentanyl may produce <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>. Therefore, use ABSTRAL with caution in patients with <span class="product-label-link" type="condition" conceptid="4228448" conceptname="Bradyarrhythmia">bradyarrhythmias</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s26"></a><a name="section-5.9"></a><p></p>
<h2>5.9 MAO Inhibitors
</h2>
<p class="First">ABSTRAL is not recommended for use in patients who have received MAO inhibitors within the past 14 days.
</p>
<p>Severe and unpredictable potentiation by MAO inhibitors has been reported with opioid analgesics.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s27"></a><a name="section-5.10"></a><p></p>
<h2>5.10 Transmucosal immediate Release Fentanyl (TIRF) Risk Evaluation and Mitigation Strategy (REMS) Access Program
</h2>
<p class="First">Because of the risk for misuse, abuse, addiction, and <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> [see <span class="Italics">Drug Abuse and <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span></span> (<a href="#s39">9</a>)], ABSTRAL is available only through a restricted program called the TIRF REMS Access program. Under the TIRF REMS Access program, outpatients, healthcare professionals who prescribe to outpatients, pharmacies, and distributors must enroll in the program. For inpatient administration (e.g., hospitals, hospices, and longterm care facilities that prescribe for inpatient use) of ABSTRAL, patient and prescriber enrollment is not required.
</p>
<p>Required components of the TIRF REMS Access program are:
</p>
<ul class="Disc">
<li>Healthcare professionals who prescribe ABSTRAL must review the prescriber educational materials for the TIRF REMS Access program, enroll in the program, and comply with the REMS requirements.
</li>
<li>To receive ABSTRAL, outpatients must understand the risks and benefits and sign a PatientPrescriber Agreement.
</li>
<li>Pharmacies that dispense ABSTRAL must enroll in the program and agree to comply with the REMS requirements.
</li>
<li>Wholesalers and distributors that distribute ABSTRAL must enroll in the program and distribute only to authorized pharmacies.
</li>
</ul>
<p>Further information, including a list of qualified pharmacies/distributors, is available at <span class="Underline">www.TIRFREMSAccess.com</span> or by calling 1-866-822-1483.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="s28"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s29"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Studies Experience
</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse event rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
</p>
<p>The safety of ABSTRAL has been evaluated in 311 opioid-tolerant cancer patients with breakthrough <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>. Two hundred and seventy (270) of these patients were treated in multiple-dose studies. The duration of therapy for patients in multiple-dose studies ranged from 1-405 days with an average duration of 131 days and with 44 patients treated for at least 12 months.
</p>
<p>The most commonly observed adverse reactions with ABSTRAL include typical opioid adverse reactions, such as <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> and <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>. Expect opioid side effects and manage them accordingly.
</p>
<p>The clinical trials of ABSTRAL were designed to evaluate safety and efficacy in treating patients with cancer and breakthrough <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>; all patients were taking concomitant opioids, such as sustained-release morphine, sustained-release oxycodone or transdermal fentanyl, for their persistent <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>.
</p>
<p>The adverse reaction data presented in <a href="#t2">Table 2</a> reflect the actual percentage of patients experiencing reactions among patients who received ABSTRAL for breakthrough <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> along with concomitant opioid use for persistent <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>. There has been no attempt to correct for concomitant use of other opioids, duration of ABSTRAL therapy or cancer-related symptoms.
</p>
<p><a href="#t2">Table 2</a> lists adverse reactions with an overall frequency of 5% or greater within the total population that occurred during titration by maximum dose received. The ability to assign ABSTRAL a dose-response relationship to these adverse reactions is limited by the titration schemes used in these studies.
</p>
<a name="t2"></a><table width="100%">
<caption><span>Table2: Adverse Reactions Which Occurred During Titration at a Frequency of ≥ 5%
</span></caption>
<col align="left" width="23.000%">
<col align="left" width="11.000%">
<col align="left" width="11.000%">
<col align="left" width="11.000%">
<col align="left" width="11.000%">
<col align="left" width="11.000%">
<col align="left" width="11.000%">
<col align="left" width="11.000%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><span class="Bold">System Organ Class Preferred term N (%)</span></td>
<td class="Botrule Rrule Toprule" align="left" valign="top">
<span class="Bold">100 mcg</span><br><span class="Bold">(n=22)</span>
</td>
<td class="Botrule Rrule Toprule" align="left" valign="top">
<span class="Bold">200 mcg</span><br><span class="Bold">(n=23)</span>
</td>
<td class="Botrule Rrule Toprule" align="left" valign="top">
<span class="Bold">300 mcg</span><br><span class="Bold">(n=55)</span>
</td>
<td class="Botrule Rrule Toprule" align="left" valign="top">
<span class="Bold">400 mcg</span><br><span class="Bold">(n=38)</span>
</td>
<td class="Botrule Rrule Toprule" align="left" valign="top">
<span class="Bold">600 mcg</span><br><span class="Bold">(n=52)</span>
</td>
<td class="Botrule Rrule Toprule" align="left" valign="top">
<span class="Bold">800 mcg</span><br><span class="Bold">(n=80)</span>
</td>
<td class="Botrule Rrule Toprule" align="left" valign="top">
<span class="Bold">Total</span><br><span class="Bold">(n=270)</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal disorders</span></span></td>
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="left" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>
</td>
<td class="Botrule Rrule" align="left" valign="top">1 (4.5)
</td>
<td class="Botrule Rrule" align="left" valign="top">4 (17.4)
</td>
<td class="Botrule Rrule" align="left" valign="top">5 (9.1)
</td>
<td class="Botrule Rrule" align="left" valign="top">1 (2.6)
</td>
<td class="Botrule Rrule" align="left" valign="top">2 (3.8)
</td>
<td class="Botrule Rrule" align="left" valign="top">2 (2.5)
</td>
<td class="Botrule Rrule" align="left" valign="top">15 (5.6)
</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous system disorders</span></span></td>
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="left" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span>
</td>
<td class="Botrule Rrule" align="left" valign="top">0
</td>
<td class="Botrule Rrule" align="left" valign="top">2 (8.7)
</td>
<td class="Botrule Rrule" align="left" valign="top">4 (7.3)
</td>
<td class="Botrule Rrule" align="left" valign="top">2 (5.3)
</td>
<td class="Botrule Rrule" align="left" valign="top">2 (3.8)
</td>
<td class="Botrule Rrule" align="left" valign="top">2 (2.5)
</td>
<td class="Botrule Rrule" align="left" valign="top">12 (4.4)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span>
</td>
<td class="Botrule Rrule" align="left" valign="top">0
</td>
<td class="Botrule Rrule" align="left" valign="top">0
</td>
<td class="Botrule Rrule" align="left" valign="top">3 (5.5)
</td>
<td class="Botrule Rrule" align="left" valign="top">2 (5.3)
</td>
<td class="Botrule Rrule" align="left" valign="top">0
</td>
<td class="Botrule Rrule" align="left" valign="top">1 (1.3)
</td>
<td class="Botrule Rrule" align="left" valign="top">6 (2.2)
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span>
</td>
<td class="Botrule Rrule" align="left" valign="top">0
</td>
<td class="Botrule Rrule" align="left" valign="top">0
</td>
<td class="Botrule Rrule" align="left" valign="top">0
</td>
<td class="Botrule Rrule" align="left" valign="top">1 (2.6)
</td>
<td class="Botrule Rrule" align="left" valign="top">3 (5.8)
</td>
<td class="Botrule Rrule" align="left" valign="top">1 (1.3)
</td>
<td class="Botrule Rrule" align="left" valign="top">5 (1.9)
</td>
</tr>
</tbody>
</table>
<p><a href="#t3">Table 3</a> lists, by successful dose, adverse reactions with an overall frequency of ≥ 5% within the total population that occurred after a successful dose had been determined.
</p>
<a name="t3"></a><table width="100%">
<caption><span>Table3: Adverse Reactions Which Occurred During Maintenance Therapy at a Frequency of ≥ 5%
</span></caption>
<col align="left" width="22.988%">
<col align="left" width="10.975%">
<col align="left" width="10.975%">
<col align="left" width="11.000%">
<col align="left" width="10.975%">
<col align="left" width="11.088%">
<col align="left" width="11.012%">
<col align="left" width="10.988%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><span class="Bold">System Organ Class Preferred term N (%)</span></td>
<td class="Botrule Rrule Toprule" align="left" valign="top">
<span class="Bold">100 mcg</span><br><span class="Bold">(n=7)</span>
</td>
<td class="Botrule Rrule Toprule" align="left" valign="top">
<span class="Bold">200 mcg</span><br><span class="Bold">(n=12)</span>
</td>
<td class="Botrule Rrule Toprule" align="left" valign="top">
<span class="Bold">300 mcg</span><br><span class="Bold">(n=22)</span>
</td>
<td class="Botrule Rrule Toprule" align="left" valign="top">
<span class="Bold">400 mcg</span><br><span class="Bold">(n=20)</span>
</td>
<td class="Botrule Rrule Toprule" align="left" valign="top">
<span class="Bold">600 mcg</span><br><span class="Bold">(n=35)</span>
</td>
<td class="Botrule Rrule Toprule" align="left" valign="top">
<span class="Bold">800 mcg</span><br><span class="Bold">(n=72)</span>
</td>
<td class="Botrule Rrule Toprule" align="left" valign="top">
<span class="Bold">Total</span><br><span class="Bold">(n=168)</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" colspan="3" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal disorders</span></span></td>
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="left" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>
</td>
<td class="Botrule Rrule" align="left" valign="top">1 (14.3)
</td>
<td class="Botrule Rrule" align="left" valign="top">0
</td>
<td class="Botrule Rrule" align="left" valign="top">2 (9.1)
</td>
<td class="Botrule Rrule" align="left" valign="top">0
</td>
<td class="Botrule Rrule" align="left" valign="top">1 (2.9)
</td>
<td class="Botrule Rrule" align="left" valign="top">6 (8.3)
</td>
<td class="Botrule Rrule" align="left" valign="top">10 (6.0)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">Stomatitis</span>
</td>
<td class="Botrule Rrule" align="left" valign="top">0
</td>
<td class="Botrule Rrule" align="left" valign="top">1 (8.3)
</td>
<td class="Botrule Rrule" align="left" valign="top">1 (4.5)
</td>
<td class="Botrule Rrule" align="left" valign="top">0
</td>
<td class="Botrule Rrule" align="left" valign="top">0
</td>
<td class="Botrule Rrule" align="left" valign="top">1 (1.4)
</td>
<td class="Botrule Rrule" align="left" valign="top">3 (1.8)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span>
</td>
<td class="Botrule Rrule" align="left" valign="top">0
</td>
<td class="Botrule Rrule" align="left" valign="top">0
</td>
<td class="Botrule Rrule" align="left" valign="top">1 (4.5)
</td>
<td class="Botrule Rrule" align="left" valign="top">2 (10.0)
</td>
<td class="Botrule Rrule" align="left" valign="top">1 (2.9)
</td>
<td class="Botrule Rrule" align="left" valign="top">4 (5.6)
</td>
<td class="Botrule Rrule" align="left" valign="top">8 (4.8)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry mouth</span>
</td>
<td class="Botrule Rrule" align="left" valign="top">0
</td>
<td class="Botrule Rrule" align="left" valign="top">0
</td>
<td class="Botrule Rrule" align="left" valign="top">0
</td>
<td class="Botrule Rrule" align="left" valign="top">1 (5.0)
</td>
<td class="Botrule Rrule" align="left" valign="top">2 (5.7)
</td>
<td class="Botrule Rrule" align="left" valign="top">0
</td>
<td class="Botrule Rrule" align="left" valign="top">3 (1.8)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" colspan="3" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous system disorders</span></span></td>
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="left" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span>
</td>
<td class="Botrule Rrule" align="left" valign="top">0
</td>
<td class="Botrule Rrule" align="left" valign="top">0
</td>
<td class="Botrule Rrule" align="left" valign="top">0
</td>
<td class="Botrule Rrule" align="left" valign="top">2 (10.0)
</td>
<td class="Botrule Rrule" align="left" valign="top">1 (2.9)
</td>
<td class="Botrule Rrule" align="left" valign="top">2 (2.8)
</td>
<td class="Botrule Rrule" align="left" valign="top">5 (3.0)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">Dysgeusia</span>
</td>
<td class="Botrule Rrule" align="left" valign="top">1 (14.3)
</td>
<td class="Botrule Rrule" align="left" valign="top">0
</td>
<td class="Botrule Rrule" align="left" valign="top">0
</td>
<td class="Botrule Rrule" align="left" valign="top">0
</td>
<td class="Botrule Rrule" align="left" valign="top">0
</td>
<td class="Botrule Rrule" align="left" valign="top">1 (1.4)
</td>
<td class="Botrule Rrule" align="left" valign="top">2 (1.2)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" colspan="3" valign="top"><span class="Bold">General disorders and administration site conditions</span></td>
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="left" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span>
</td>
<td class="Botrule Rrule" align="left" valign="top">0
</td>
<td class="Botrule Rrule" align="left" valign="top">0
</td>
<td class="Botrule Rrule" align="left" valign="top">0
</td>
<td class="Botrule Rrule" align="left" valign="top">1 (5.0)
</td>
<td class="Botrule Rrule" align="left" valign="top">2 (5.7)
</td>
<td class="Botrule Rrule" align="left" valign="top">0
</td>
<td class="Botrule Rrule" align="left" valign="top">3 (1.8)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" colspan="3" valign="top"><span class="Bold">Injury, <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> and procedural complications</span></td>
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="left" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Accidental <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>
</td>
<td class="Botrule Rrule" align="left" valign="top">1 (14.3)
</td>
<td class="Botrule Rrule" align="left" valign="top">0
</td>
<td class="Botrule Rrule" align="left" valign="top">0
</td>
<td class="Botrule Rrule" align="left" valign="top">0
</td>
<td class="Botrule Rrule" align="left" valign="top">0
</td>
<td class="Botrule Rrule" align="left" valign="top">0
</td>
<td class="Botrule Rrule" align="left" valign="top">1 (0.6)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" colspan="3" valign="top"><span class="Bold">Respiratory, thoracic and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">mediastinal disorders</span></span></td>
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="left" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnoea</span>
</td>
<td class="Botrule Rrule" align="left" valign="top">0
</td>
<td class="Botrule Rrule" align="left" valign="top">1 (8.3)
</td>
<td class="Botrule Rrule" align="left" valign="top">0
</td>
<td class="Botrule Rrule" align="left" valign="top">0
</td>
<td class="Botrule Rrule" align="left" valign="top">0
</td>
<td class="Botrule Rrule" align="left" valign="top">0
</td>
<td class="Botrule Rrule" align="left" valign="top">1 (0.6)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" colspan="3" valign="top"><span class="Bold">Skin and subcutaneous disorders</span></td>
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="left" valign="top"></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">Hyperhidrosis</span>
</td>
<td class="Botrule Rrule" align="left" valign="top">1 (14.3)
</td>
<td class="Botrule Rrule" align="left" valign="top">0
</td>
<td class="Botrule Rrule" align="left" valign="top">0
</td>
<td class="Botrule Rrule" align="left" valign="top">0
</td>
<td class="Botrule Rrule" align="left" valign="top">0
</td>
<td class="Botrule Rrule" align="left" valign="top">1 (1.4)
</td>
<td class="Botrule Rrule" align="left" valign="top">2 (1.2)
</td>
</tr>
</tbody>
</table>
<p>The frequencies listed below represent adverse reactions that occurred in ≥ 1% of patients from two clinical trials who experienced that reaction while receiving ABSTRAL. Reactions are classified by system organ class.
</p>
<p><span class="Bold">Adverse Reactions (≥ 1%)</span></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="321588" conceptname="Heart disease">Cardiac disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>.
</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="375252" conceptname="Disorder of eye">Eye disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">vision blurred</span>.
</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">abdominal pain upper</span>, <span class="product-label-link" type="condition" conceptid="138463" conceptname="Aphthous ulcer of mouth">aphthous stomatitis</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="4324848" conceptname="Ulceration of gingivae">gingival ulceration</span>, <span class="product-label-link" type="condition" conceptid="4010028" conceptname="Impaired gastric emptying">impaired gastric emptying</span>, <span class="product-label-link" type="condition" conceptid="4271702" conceptname="Lip ulcer">lip ulceration</span>, <span class="product-label-link" type="condition" conceptid="4094986" conceptname="Ulcer of mouth">mouth ulceration</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4152197" conceptname="Stomach ache">stomach discomfort</span>, <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span>, <span class="product-label-link" type="condition" conceptid="432941" conceptname="Disorder of tongue">tongue disorder</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>.
</p>
<p><span class="Bold">General disorders and administration site conditions:</span> <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="441260" conceptname="Drug withdrawal">drug withdrawal syndrome</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>.
</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="440371" conceptname="Disorder of immune function">Immune system disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="439224" conceptname="Drug allergy">drug hypersensitivity</span>.
</p>
<p><span class="Bold">Injury, <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> and procedural complications:</span> accidental <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>.
</p>
<p><span class="Bold">Metabolism and nutrition disorders:</span> <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">decreased appetite</span>.
</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous system disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">amnesia</span>, <span class="product-label-link" type="condition" conceptid="4096147" conceptname="Poor concentration">disturbance in attention</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">dysgeusia</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">hypoesthesia</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="444223" conceptname="Sense of smell altered">parosmia</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>.
</p>
<p><span class="Bold">Psychiatric disorders:</span> <span class="product-label-link" type="condition" conceptid="4197184" conceptname="Pseudobulbar affect">affect lability</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusional state</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">disorientation</span>, <span class="product-label-link" type="condition" conceptid="4148767" conceptname="Dysphoric mood">dysphoria</span>, <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">euphoric mood</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="436222" conceptname="Altered mental status">mental status changes</span>, <span class="product-label-link" type="condition" conceptid="432590" conceptname="Delusional disorder">paranoia</span>, <span class="product-label-link" type="condition" conceptid="435524" conceptname="Sleep disorder">sleep disorder</span>.
</p>
<p><span class="Bold">Reproductive system and <span class="product-label-link" type="condition" conceptid="77030" conceptname="Disorder of breast">breast disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">erectile dysfunction</span>.
</p>
<p><span class="Bold">Respiratory, thoracic and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">mediastinal disorder</span>:</span> <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, oropharyngeal <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="4194507" conceptname="Feeling of throat tightness">throat tightness</span>.
</p>
<p><span class="Bold">Skin and subcutaneous disorders:</span> <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">hyperhidrosis</span>, <span class="product-label-link" type="condition" conceptid="4181178" conceptname="Night sweats">night sweats</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="4316083" conceptname="Skin lesion">skin lesion</span>.
</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">Vascular disorders</span></span>: <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="s30"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS
</h1>
<p class="First">Fentanyl is metabolized mainly via the human cytochrome P450 3A4 isoenzyme system (CYP3A4); therefore potential interactions may occur when ABSTRAL is given concurrently with agents that affect CYP3A4 activity.
</p>
<p>The concomitant use of ABSTRAL with CYP3A4 <span class="Underline">inhibitors</span> (e.g., indinavir, nelfinavir, ritonavir, clarithromycin, itraconazole, ketoconazole, nefazodone, saquinavir, telithromycin, aprepitant, diltiazem, erythromycin, fluconazole, grapefruit juice, verapamil, or cimetidine) may result in a potentially dangerous increase in fentanyl plasma concentrations, which could increase or prolong adverse drug effects and may cause potentially fatal <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>. Patients receiving ABSTRAL who begin therapy with, or increase the dose of, CYP3A4 inhibitors need to be carefully monitored for signs of opioid toxicity over an extended period of time. Increase dosage conservatively.
</p>
<p>The concomitant use of ABSTRAL with CYP3A4 <span class="Underline">inducers</span> (e.g., barbiturates, carbamazepine, efavirenz, glucocorticoids, modafinil, nevirapine, oxcarbazepine, phenobarbital, phenytoin, pioglitazone, rifabutin, rifampin, St. John's wort, or troglitazone) may result in a decrease in fentanyl plasma concentrations, which could decrease the efficacy of ABSTRAL.
</p>
<p>Patients receiving ABSTRAL who stop therapy with, or decrease the dose of, CYP3A4 inducers need to be monitored for signs of increased ABSTRAL activity and the dose of ABSTRAL must be adjusted accordingly.
</p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="s31"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS
</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="s32"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy - Category C
</h2>
<p class="First">There are no adequate and well-controlled studies in pregnant women.
</p>
<p>Use ABSTRAL during pregnancy only if the potential benefit justifies the potential risk to the fetus. No epidemiological studies of congenital anomalies in infants born to women treated with fentanyl during pregnancy have been reported.
</p>
<p>Chronic maternal treatment with fentanyl during pregnancy has been associated with transient <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, behavioral changes, or <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> in newborn infants characteristic of neonatal abstinence syndrome.
</p>
<p>In women treated acutely with intravenous or epidural fentanyl during labor, symptoms of neonatal respiratory or neurological <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> were no more frequent than would be expected in infants of untreated mothers.
</p>
<p>Transient neonatal muscular <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">rigidity</span> has been observed in infants whose mothers were treated with intravenous fentanyl.
</p>
<p>Fentanyl is embryocidal in rats as evidenced by increased resorptions in pregnant rats at doses of 30 mcg/kg intravenously or 160 mcg/kg subcutaneously. Conversion to human equivalent doses indicates this is within the range of the human recommended dosing for ABSTRAL.
</p>
<p>Fentanyl citrate was not teratogenic when administered to pregnant animals. Published studies demonstrated that administration of fentanyl (10, 100, or 500 mcg/kg/day) to pregnant rats from day 7 to 21, of their 21 day gestation, via implanted microosmotic minipumps, was not teratogenic (the high dose was approximately 6times the human dose of 800 mcg per <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> episode on a mcg/m<span class="Sup">2</span> basis). Intravenous administration of fentanyl (10 mcg/kg or 30 mcg/kg) to pregnant female rats from gestation day 6 to 18, was embryo- or feto-toxic, and caused a slightly increased mean delivery time in the 30 mcg/kg/day group, but was not teratogenic.
</p>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="s33"></a><a name="section-8.2"></a><p></p>
<h2>8.2 Labor and Delivery
</h2>
<p class="First">Fentanyl readily crosses the placenta. Therefore do not use ABSTRAL during labor and delivery (including caesarean section) since it may cause <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> in the fetus or in the newborn infant.
</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="s34"></a><a name="section-8.3"></a><p></p>
<h2>8.3 Nursing Mothers
</h2>
<p class="First">Fentanyl is excreted in human milk; therefore, do not use ABSTRAL in women who are nursing because of the possibility of sedation and/or <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> in their infants. Symptoms of opioid withdrawal may occur in infants at the cessation of nursing by women using ABSTRAL.
</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="s35"></a><a name="section-8.4"></a><p></p>
<h2>8.4 Pediatric Use
</h2>
<p class="First">The safety and efficacy of ABSTRAL have not been established in patients below 18 years of age.
</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="s36"></a><a name="section-8.5"></a><p></p>
<h2>8.5 Geriatric Use
</h2>
<p class="First">Of the 270 opioid tolerant patients with breakthrough cancer <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in the Phase 3 clinical studies of Abstral, 58 (21%) were 65 years of age and older. There was no difference in the median titrated dose in patients aged 65 years and older compared to those &lt;65 years. No clinically meaningful difference was noted in the safety profile of the group 65 years of age and older as compared to younger patients in ABSTRAL clinical trials.
</p>
<p>Elderly patients have been shown to be more sensitive to the effects of fentanyl when administered intravenously, compared with the younger adult population. Therefore, exercise caution when individually titrating ABSTRAL in elderly patients to provide adequate efficacy while minimizing risk.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s37"></a><a name="section-8.6"></a><p></p>
<h2>8.6 Patients with Renal and <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>
</h2>
<p class="First">Insufficient information exists to make recommendations regarding the use of ABSTRAL in patients with impaired renal or hepatic function. Fentanyl is metabolized primarily via human cytochrome P450 3A4 isoenzyme system and the inactive metabolite is mostly eliminated in urine. If the drug is used in these patients, use the drug with caution because of the reduced hepatic metabolism and renal excretion capacity in such patients.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s38"></a><a name="section-8.7"></a><p></p>
<h2>8.7 Gender
</h2>
<p class="First">Both male and female opioid-tolerant cancer patients were studied for the treatment of breakthrough cancer <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>. No clinically relevant gender differences were noted either in efficacy or in observed adverse reactions.
</p>
</div>
</div>
<div class="Section" data-sectionCode="42227-9">
<a name="s39"></a><a name="section-9"></a><p></p>
<h1>9 DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span>
</h1>
<div class="Section" data-sectionCode="34085-1">
<a name="s40"></a><a name="section-9.1"></a><p></p>
<h2>9.1 Controlled Substance
</h2>
<p class="First">ABSTRAL contains fentanyl, a Schedule II substance. Schedule II opioid substances such as fentanyl, hydromorphone, methadone, morphine, oxycodone, and oxymorphone have a high potential for abuse and addiction. ABSTRAL is also subject to misuse and criminal diversion.
</p>
</div>
<div class="Section" data-sectionCode="34086-9">
<a name="s41"></a><a name="section-9.2"></a><p></p>
<h2>9.2 Abuse and Addiction
</h2>
<p class="First">Manage the handling of ABSTRAL to minimize the risk of misuse, including the restriction of access and accounting procedures as appropriate to the clinical setting and as required by law [see <span class="Italics">How Supplied/Storage and Handling</span> (<a href="#s67">16.2</a>, <a href="#s68">16.3</a>)].
</p>
<p>Concerns about abuse, addiction, and diversion must not prevent the proper management of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>. However, all patients treated with opioids require careful monitoring for signs of abuse and addiction, because use of opioid analgesic products carries the risk of addiction even under appropriate medical use.
</p>
<p>Addiction is a primary, chronic, neurobiologic disease, with genetic, psychosocial, and environmental factors influencing its development and manifestations. It is characterized by behaviors that include one or more of the following: impaired control over drug use, compulsive use, continued use despite harm, and craving. <span class="product-label-link" type="condition" conceptid="440069" conceptname="Drug dependence">Drug addiction</span> is a treatable disease, utilizing a multidisciplinary approach, but relapse is common. "Drug-seeking" behavior is very common in addicts and drug abusers.
</p>
<p>Abuse and addiction are separate and distinct from physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> and tolerance. Be aware that addiction may not be accompanied by concurrent tolerance and symptoms of physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> in all addicts. In addition, abuse of opioids can occur in the absence of addiction and is characterized by misuse for non-medical purposes, often in combination with other psychoactive substances. Since ABSTRAL may be diverted for nonmedical use, careful record keeping of prescribing information, including quantity, frequency, and renewal requests is strongly advised.
</p>
<p>Proper patient assessment, safe prescribing practices, periodic re-evaluation of therapy, and proper dispensing and storage are appropriate measures that help to limit abuse of opioid drugs.
</p>
<p>Contact your State Professional Licensing Board, or State Controlled Substances Authority for information on how to prevent and detect abuse or diversion of this product.
</p>
</div>
<div class="Section" data-sectionCode="34087-7">
<a name="s42"></a><a name="section-9.3"></a><p></p>
<h2>9.3 <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span>
</h2>
<p class="First">Physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> is not ordinarily a concern in the treatment of patients with chronic cancer <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, and <span class="product-label-link" type="condition" conceptid="4029621" conceptname="Fear">fear</span> of tolerance and physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> must not deter using opiate doses that adequately relieve the <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>. Guide the administration of Abstral by the response of the patient.
</p>
<p>Opioid analgesics may cause physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> that can result in withdrawal symptoms in patients who abruptly discontinue the drug. Withdrawal also may be precipitated through the administration of drugs with opioid antagonist activity (e.g., naloxone, nalmefene) or mixed agonist/antagonist analgesics (pentazocine, butorphanol, buprenorphine, nalbuphine).
</p>
<p>Physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> usually does not occur to a clinically significant degree until after several weeks of continued opioid usage. Tolerance, in which increasingly larger doses are required in order to produce the same degree of <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span>, is initially manifested by a shortened duration of <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesic effect</span>, and subsequently, by decreases in the intensity of <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span>.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="s43"></a><a name="section-10"></a><p></p>
<h1>10 OVERDOSAGE
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s44"></a><a name="section-10.1"></a><p></p>
<h2>10.1 Clinical Presentation
</h2>
<p class="First">The manifestations of ABSTRAL overdosage are expected to be similar in nature to intravenous fentanyl and other opioids, and are an extension of its pharmacological actions with the most serious significant effect being <span class="product-label-link" type="condition" conceptid="312603" conceptname="Hypoventilation">hypoventilation</span> [see <span class="Italics">Clinical Pharmacology</span> (<a href="#s52">12.2</a>)].
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s45"></a><a name="section-10.2"></a><p></p>
<h2>10.2 Immediate Management
</h2>
<p class="First">Immediate management of opioid <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> includes removal of the ABSTRAL tablet, if still in the mouth, ensuring a patent airway, physical and verbal stimulation of the patient, and assessment of level of consciousness, ventilatory and circulatory status.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s46"></a><a name="section-10.3"></a><p></p>
<h2>10.3 Treatment of Overdosage (Accidental Ingestion) in the Opioid NON-Tolerant Person
</h2>
<p class="First">Provide ventilatory support, obtain intravenous access, and administer naloxone or other opioid antagonists as clinically indicated. The duration of <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> following <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> may be longer than the effects of the opioid antagonist's action (e.g., the half-life of naloxone ranges from 30 to 81 minutes) and repeated administration may be necessary. Consult the package insert of the individual opioid antagonist for details.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s47"></a><a name="section-10.4"></a><p></p>
<h2>10.4 Treatment of Overdosage in Opioid-Tolerant Patients
</h2>
<p class="First">Provide ventilatory support and obtain intravenous access as clinically indicated. Judicious use of naloxone or another opioid antagonist may be warranted in some instances, but at the risk of precipitating an acute withdrawal syndrome.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s48"></a><a name="section-10.5"></a><p></p>
<h2>10.5 General Considerations for <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Overdose</span>
</h2>
<p class="First">Management of severe ABSTRAL <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> includes: securing a patent airway, assisting or controlling ventilation and establishing intravenous access. In the presence of <span class="product-label-link" type="condition" conceptid="312603" conceptname="Hypoventilation">hypoventilation</span> or <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span>, assist or control ventilation, and administer oxygen as indicated.
</p>
<p>Carefully observe and appropriately manage patients with <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> until their clinical condition is well controlled.
</p>
<p>Although <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">muscle rigidity</span> interfering with respiration has not been seen following the use of ABSTRAL, this is possible with fentanyl and other opioids. If it occurs, manage it by using assisted or controlled ventilation, by an opioid antagonist, and as a final alternative, by a neuromuscular blocking agent.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="s49"></a><a name="section-11"></a><p></p>
<h1>11 DESCRIPTION
</h1>
<p class="First">ABSTRAL (fentanyl) sublingual tablet is a solid formulation of fentanyl citrate, a potent opioid analgesic intended for oral sublingual administration. ABSTRAL is formulated as a white tablet available in six strengths, distinguishable by the shape of the tablet and by de-bossing on the tablet surface.
</p>
<p><span class="Bold">Active Ingredient:</span> Fentanyl citrate, USP is N-(1-Phenethyl-4-piperidyl) propionanilide citrate (1:1). Fentanyl is a highly lipophilic compound (octanol-water partition coefficient at pH 7.4 is 816:1) that is freely soluble in organic solvents and sparingly soluble in water (1:40). The molecular weight of the free base is 336.5 (the citrate salt is 528.6). The pKa of the tertiary nitrogens are 7.3 and 8.4. The compound has the following structural formula:
</p>
<p><a name="f02"></a><img alt="Structural Formula
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=f969e2bc-6297-4e29-89d3-a3685a2c7c6b&amp;name=abs02-0001-02.jpg"></p>
<p>All tablet strengths are expressed as the amount of fentanyl free base, e.g., the 100 mcg strength tablet contains 100 mcg of fentanyl free base.
</p>
<p><span class="Bold">Inactive Ingredients:</span> Croscarmellose sodium, magnesium stearate, mannitol, and silicified microcrystalline cellulose.
</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="s50"></a><a name="section-12"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY
</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="s51"></a><a name="section-12.1"></a><p></p>
<h2>12.1 Mechanism of Action
</h2>
<p class="First">Fentanyl is a pure opioid agonist whose principal therapeutic action is <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span>. Other members of the class known as opioid agonists include substances such as morphine, oxycodone, hydromorphone, codeine, and hydrocodone.
</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="s52"></a><a name="section-12.2"></a><p></p>
<h2>12.2 Pharmacodynamics
</h2>
<p class="First">Pharmacological effects of opioid agonists include anxiolysis, <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">euphoria</span>, feelings of relaxation, <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="435279" conceptname="Tonic pupillary reaction">miosis</span>, <span class="product-label-link" type="condition" conceptid="4009383" conceptname="Cough suppression">cough suppression</span>, and <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span>. Like all pure opioid agonist analgesics, with increasing doses there is increasing <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span>, unlike with mixed agonist/antagonists or non-opioid analgesics, where there is a limit to the <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesic effect</span> with increasing doses. With pure opioid agonist analgesics, there is no defined maximum dose; the ceiling to analgesic effectiveness is imposed only by side effects, the more serious of which may include <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> and <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>. <span class="Underline"><span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">Analgesia</span></span></p>
<p>In general, the effective concentration and the concentration at which toxicity occurs increase with increasing tolerance with any and all opioids. The rate of development of tolerance varies widely among individuals. As a result, individually titrate the dose of ABSTRAL to achieve the desired effect [see <span class="Italics">Dosage and Administration</span> (<a href="#s7">2</a>)].
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s53"></a><a name="section-12.2.1"></a><p></p>
<p class="First"><span class="Underline">Central Nervous System</span></p>
<p>The precise mechanism of the analgesic action is unknown although fentanyl is known to be a μ-opioid receptor agonist. Specific CNS opioid receptors for endogenous compounds with opioid-like activity have been identified throughout the brain and spinal cord and play a role in the <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesic effects</span> of this drug.
</p>
<p>Fentanyl produces <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> by direct action on brain stem respiratory centers. The <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> involves both a reduction in the responsiveness of the brain stem to increases in <span class="product-label-link" type="condition" conceptid="4135927" conceptname="Carbon dioxide">carbon dioxide</span> and to electrical stimulation.
</p>
<p>Fentanyl causes <span class="product-label-link" type="condition" conceptid="435279" conceptname="Tonic pupillary reaction">miosis</span> even in total darkness. Pinpoint pupils are a sign of opioid <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> but are not pathognomonic (e.g., pontine lesions of hemorrhagic or ischemic origin may produce similar findings).
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s54"></a><a name="section-12.2.2"></a><p></p>
<p class="First"><span class="Underline">Gastrointestinal System</span></p>
<p>Fentanyl causes a reduction in motility associated with an increase in smooth muscle tone in the antrum of the stomach and in the duodenum. Digestion of food is delayed in the small intestine and propulsive contractions are decreased. Propulsive peristaltic waves in the colon are decreased, while tone may be increased to the point of spasm resulting in <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>. Other opioid induced-effects may include a reduction in gastric, biliary and pancreatic secretions, spasm of the sphincter of Oddi, and transient elevations in serum amylase.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s55"></a><a name="section-12.2.3"></a><p></p>
<p class="First"><span class="Underline">Cardiovascular System</span></p>
<p>Fentanyl may produce release of histamine with or without associated peripheral vasodilation. Manifestations of histamine release and/or peripheral vasodilation may include <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="442546" conceptname="Red eye">red eyes</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, and/or <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s56"></a><a name="section-12.2.4"></a><p></p>
<p class="First"><span class="Underline">Endocrine System</span></p>
<p>Opioid agonists have been shown to have a variety of effects on the secretion of hormones. Opioids inhibit the secretion of ACTH, cortisol, and luteinizing hormone (LH) in humans. They also stimulate prolactin secretion, growth hormone (GH) secretion, and pancreatic secretion of insulin and glucagon in humans and other species (e.g., rats and dogs). Thyroid stimulating hormone (TSH) has been shown to be both inhibited and stimulated by opioids.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s57"></a><a name="section-12.2.5"></a><p></p>
<p class="First"><span class="Underline">Respiratory System</span></p>
<p>All opioid mu-receptor agonists, including fentanyl, produce dose-dependent <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>. The risk of <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> is less in patients receiving chronic opioid therapy who develop tolerance to these effects. Peak respiratory depressive effects may be seen as early as 15 to 30 minutes from the start of oral transmucosal fentanyl citrate administration and may persist for several hours.
</p>
<p>Serious or fatal <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> can occur even at recommended doses. Fentanyl depresses the <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> reflex as a result of its CNS activity. Although not observed with oral transmucosal fentanyl products in clinical trials, fentanyl given rapidly by intravenous injection in large doses may cause <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">rigidity</span> in the muscles of respiration resulting in respiratory difficulties. Therefore, be aware of this potential complication [see <span class="Italics">Boxed Warning - Warnings: Importance Of Proper Patient Selection and Potential for Abuse, Contraindications</span> (<a href="#s16">4</a>), <span class="Italics">Warnings And Precautions</span> (<a href="#s18">5.1</a>), <span class="Italics">Adverse Reactions</span> (<a href="#s28">6</a>), and <span class="Italics">Overdosage</span> (<a href="#s43">10</a>)].
</p>
</div>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="s58"></a><a name="section-12.3"></a><p></p>
<h2>12.3 Pharmacokinetics
</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s59"></a><a name="section-12.3.1"></a><p></p>
<p class="First"><span class="Underline">Absorption</span></p>
<p>Fentanyl is a highly lipophilic drug. Orally administered fentanyl undergoes pronounced hepatic and intestinal first pass effects. Absorption of fentanyl from ABSTRAL sublingual tablets is mainly through the oral mucosa.
</p>
<p>The bioavailability of ABSTRAL sublingual tablets has been calculated to be 54%.
</p>
<p>Dose proportionality across the 100 mcg to 800 mcg ABSTRAL dose range has been demonstrated (Table4). Mean plasma fentanyl levels following single doses of ABSTRAL are shown in <a href="#fig1">Figure 1</a>. The median time to maximum plasma concentration (Tmax) across these four doses of ABSTRAL varied from 30 to 60 minutes (range of 15 - 240 minutes).
</p>
<p><a name="fig1"></a><span class="Bold">Figure 1: Mean (+/- SD) Plasma Fentanyl Concentration versus Time after Administration of Single Doses of 100 mcg, 200 mcg, 400 mcg and 800 mcg ABSTRAL to Healthy Subjects</span></p>
<p><a name="f03"></a><img alt="Figure 1
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=f969e2bc-6297-4e29-89d3-a3685a2c7c6b&amp;name=abs02-0001-03.jpg"></p>
<p>Pharmacokinetic parameters are presented in <a href="#t4">Table 4</a>.
</p>
<a name="t4"></a><table width="100%">
<caption><span>Table 4. Mean (CV%) Fentanyl Pharmacokinetic Parameters after Single-Dose Administration of 100, 200, 400 and 800 mcg Doses of ABSTRAL to Healthy Subjects (n=12 per Dose Level)
</span></caption>
<col align="left" width="16.667%">
<col align="left" width="16.617%">
<col align="left" width="16.717%">
<col align="left" width="16.667%">
<col align="left" width="16.667%">
<col align="left" width="16.667%">
<tfoot><tr class="First Last"><td align="left" colspan="6" valign="top"><p class="First Footnote">a: median (range)
</p></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" rowspan="2" valign="top"><span class="Bold">Parameter</span></td>
<td class="Botrule Rrule Toprule" align="center" rowspan="2" valign="top"><span class="Bold">Unit</span></td>
<td class="Botrule Toprule" align="left" valign="top"></td>
<td class="Botrule Toprule" align="center" colspan="2" valign="top"><span class="Bold">Abstral dose</span></td>
<td class="Botrule Rrule Toprule" align="left" valign="top"></td>
</tr>
<tr>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">100 mcg</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">200 mcg</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">400 mcg</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">800 mcg</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">C<span class="Sub">max</span>
</td>
<td class="Botrule Rrule" align="left" valign="top">(ng/mL)
</td>
<td class="Botrule Rrule" align="left" valign="top">0.187 (33)
</td>
<td class="Botrule Rrule" align="left" valign="top">0.302 (31)
</td>
<td class="Botrule Rrule" align="left" valign="top">0.765 (38)
</td>
<td class="Botrule Rrule" align="left" valign="top">1.42 (33)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">T<span class="Sub">max</span>a
</td>
<td class="Botrule Rrule" align="left" valign="top">(min)
</td>
<td class="Botrule Rrule" align="left" valign="top">30 [19-120]
</td>
<td class="Botrule Rrule" align="left" valign="top">52 [16-240]
</td>
<td class="Botrule Rrule" align="left" valign="top">60 [30-120]
</td>
<td class="Botrule Rrule" align="left" valign="top">30 [15-60]
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">AUC0-inf
</td>
<td class="Botrule Rrule" align="left" valign="top">(ng.h/mL)
</td>
<td class="Botrule Rrule" align="left" valign="top">0.974 (34)
</td>
<td class="Botrule Rrule" align="left" valign="top">1.92 (27)
</td>
<td class="Botrule Rrule" align="left" valign="top">5.49 (35)
</td>
<td class="Botrule Rrule" align="left" valign="top">8.95 (33)
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">T1/2
</td>
<td class="Botrule Rrule" align="left" valign="top">(h)
</td>
<td class="Botrule Rrule" align="left" valign="top">5.02 (51)
</td>
<td class="Botrule Rrule" align="left" valign="top">6.67 (30)
</td>
<td class="Botrule Rrule" align="left" valign="top">13.5 (37)
</td>
<td class="Botrule Rrule" align="left" valign="top">10.1 (34)
</td>
</tr>
</tbody>
</table>
<p>In another study, dose proportionality between 800 mcg and 1600 mcg in Cmax and AUC has also been demonstrated.
</p>
<p>Pharmacokinetic studies have shown that multiple tablets are bioequivalent to single tablets of the equivalent dose.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s60"></a><a name="section-12.3.2"></a><p></p>
<p class="First"><span class="Underline">Distribution</span></p>
<p>Fentanyl is highly lipophilic. Animal data showed that following absorption, fentanyl is rapidly distributed to the brain, heart, lungs, kidneys and spleen followed by a slower redistribution to muscles and fat. The plasma protein binding of fentanyl is 80-85%. The main binding protein is alpha-1-acid glycoprotein, but both albumin and lipoproteins contribute to some extent. The free fraction of fentanyl increases with <span class="product-label-link" type="condition" conceptid="435517" conceptname="Acidosis">acidosis</span>. The mean volume of distribution at steady state (Vss) was 4 L/kg. <span class="Underline">Metabolism</span></p>
<p>Fentanyl is metabolized in the liver and in the intestinal mucosa to norfentanyl by cytochrome P450 3A4 isoform. Norfentanyl was not found to be pharmacologically active in animal studies [see <span class="Italics">Drug Interactions (<a href="#s30">7</a>)].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s61"></a><a name="section-12.3.3"></a><p></p>
<p class="First"><span class="Underline">Elimination</span></p>
<p>Fentanyl is more than 90% eliminated by biotransformation to N-dealkylated and hydroxylated inactive metabolites. Less than 7% of the dose is excreted unchanged in the urine, and only about 1% is excreted unchanged in the feces. The metabolites are mainly excreted in the urine, while fecal excretion is less important. The total plasma clearance of fentanyl was 0.5 L/hr/kg (range 0.3 - 0.7 L/ hr/kg).
</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="s62"></a><a name="section-13"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY
</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="s63"></a><a name="section-13.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
</h2>
<p class="First">Long-term studies in animals have not been performed to evaluate the carcinogenic potential of fentanyl.
</p>
<p>Fentanyl citrate was not mutagenic in the <span class="Italics">in vitro</span> Ames reverse mutation assay in <span class="Italics">S. typhimurium</span> or <span class="Italics">E. coli</span>, or the mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> mutagenesis assay, and was not clastogenic in the <span class="Italics">in vivo</span> mouse micronucleus assay.
</p>
<p>Fentanyl has been shown to impair fertility in rats at doses of 30 mcg/kg intravenously and 160 mcg/kg subcutaneously. Conversion to the human equivalent doses indicates that this is within the range of the human recommended dosing for ABSTRAL.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="s64"></a><a name="section-14"></a><p></p>
<h1>14 CLINICAL STUDIES
</h1>
<p class="First">The efficacy of ABSTRAL was investigated in a clinical trial in opioid tolerant adult patients experiencing breakthrough cancer <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>. Breakthrough cancer <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> was defined as a transient flare of moderate-to-severe <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> occurring in patients with cancer experiencing persistent cancer <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> otherwise controlled with maintenance doses of opioid medications including at least 60 mg morphine/day, 50 mcg transdermal fentanyl/hour, or an equianalgesic dose of another opioid for 1 week or longer. All patients were on stable doses of either long-acting oral opioids or transdermal fentanyl for their persistent cancer <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>.
</p>
<p>A double-blind, placebo-controlled, crossover study was performed in patients with cancer to evaluate the effectiveness of ABSTRAL for the treatment of breakthrough cancer <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>. Open-label titration identified a dose of ABSTRAL in which a patient obtained adequate <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> with tolerable side effects, within the range of 100 mcg to 800 mcg. In the double-blind efficacy study, patients who identified a successful dose were randomized to a sequence of 10 treatments; seven with ABSTRAL and three with placebo.
</p>
<p>Of the 131 patients who entered the titration phase of the study, 78 (60%) achieved a successful dose during the titration phase. Sixty- six patients entered the double-blind phase and 60 completed the study. The dose of ABSTRAL was determined by titration starting at 100 mcg. The final titrated dose of ABSTRAL for breakthrough cancer <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> was not predicted from the daily maintenance dose of opioid used to manage the persistent cancer <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>. In a second open-label safety study using an identical titration regimen, 96 of 139 patients (69%) who entered the study titrated to a dose in which the patient obtained adequate <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> with tolerable side effects during the titration phase. <a href="#t5">Table 5</a> presents the final titrated dose for both the doubleblind efficacy and open-label safety studies.
</p>
<a name="t5"></a><table width="100%">
<caption><span>Table 5: Final dose of ABSTRAL following initial titration in all clinical efficacy and safety studies
</span></caption>
<col align="left" width="50.000%">
<col align="left" width="50.000%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><span class="Bold">ABSTRAL Dose</span></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><span class="Bold">N=174 n (%)</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top">100 mcg
</td>
<td class="Botrule Rrule" align="center" valign="top">11 (6)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top">200 mcg
</td>
<td class="Botrule Rrule" align="center" valign="top">15 (9)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top">300 mcg
</td>
<td class="Botrule Rrule" align="center" valign="top">35 (20)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top">400 mcg
</td>
<td class="Botrule Rrule" align="center" valign="top">25 (14)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top">600 mcg
</td>
<td class="Botrule Rrule" align="center" valign="top">40 (23)
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="center" valign="top">800 mcg
</td>
<td class="Botrule Rrule" align="center" valign="top">48 (28)
</td>
</tr>
</tbody>
</table>
<p>The primary outcome measure, the mean sum of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> intensity difference at 30 minutes (SPID30) for ABSTRAL-treated episodes was statistically significantly higher than for placebo-treated episodes. 
</p>
<p><a name="fig2"></a><span class="Bold">Figure 2: Mean <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> Intensity Difference (±SE) for ABSTRAL Compared to Placebo</span></p>
<p><a name="f04"></a><img alt="Figure 2
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=f969e2bc-6297-4e29-89d3-a3685a2c7c6b&amp;name=abs02-0001-04.jpg"></p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="s65"></a><a name="section-15"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING
</h1>
<div class="Section" data-sectionCode="44425-7">
<a name="s66"></a><a name="section-15.1"></a><p></p>
<h2>16.1 Storage and Handling
</h2>
<p class="First">ABSTRAL is supplied in individually sealed child-resistant <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> packages contained in a cardboard outer carton, in pack sizes of 12 (100 mcg, 200 mcg, 300 mcg and 400 mcg strengths) or 32 (all strengths) tablets. The packaging is color-coded for each ABSTRAL tablet strength.
</p>
<p>The amount of fentanyl contained in ABSTRAL can be fatal to a child, individual for whom it is not prescribed or non-opioid tolerant adult. Patients and their caregivers must be instructed to keep ABSTRAL out of the reach of children [see <span class="Italics">Boxed Warning - Warnings: Potential For Abuse and Importance Of Proper Patient Selection</span> and <span class="Italics">Warnings And Precautions</span> (<a href="#s17">5</a>), and <span class="Italics">Patient Counseling Information</span> (17.1)].
</p>
<p>Store at 20-25°C (68-77°F); excursions permitted between 15-30°C (59-86°F) [see USP Controlled Room Temperature]. Protect from moisture.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s67"></a><a name="section-15.2"></a><p></p>
<h2>16.2 Disposal of ABSTRAL
</h2>
<p class="First">Patients and their household members must be advised to dispose of any tablets remaining from a prescription as soon as they are no longer needed. Instructions are included in <span class="Italics">Patient Counseling Information</span> (17.2) and in the <span class="Italics"><a href="#s70">Medication Guide</a></span>.
</p>
<p>To dispose of any unused ABSTRAL tablets, remove them from the <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> cards and flush down the toilet. Do not dispose of the ABSTRAL <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> cards or cartons down the toilet.
</p>
<p>If additional assistance is required, call Galena Biopharma, Inc. at 1-888-227-8725.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s68"></a><a name="section-15.3"></a><p></p>
<h2>16.3 How Supplied
</h2>
<p class="First">ABSTRAL is supplied in six dosage strengths. Tablets are supplied in child-resistant, protective <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> cards with peelable foil. Each <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> card contains 4 tablets, in pack sizes of 12 (100 mcg, 200 mcg, 300 mcg and 400 mcg strengths) or 32 (all strengths) tablets. Each tablet is white in color, with the strength distinguishable by the shape of the dosage unit and by de-bossing on the tablet surface:
</p>
<table width="100%">
<col align="left" width="15.800%">
<col align="left" width="16.400%">
<col align="left" width="16.400%">
<col align="left" width="19.933%">
<col align="left" width="15.733%">
<col align="left" width="15.733%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">
<span class="Bold">Dosage</span><br><span class="Bold">Strength (fentanyl base)</span>
</td>
<td class="Botrule Rrule Toprule" align="left" valign="top"><span class="Bold">Tablet Shape</span></td>
<td class="Botrule Rrule Toprule" align="left" valign="top"><span class="Bold">Tablet Markings</span></td>
<td class="Botrule Rrule Toprule" align="left" valign="top">
<span class="Bold">Carton/<span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span></span><br><span class="Bold">Package Color</span>
</td>
<td class="Botrule Rrule Toprule" align="left" valign="top"><span class="Bold">Pack size</span></td>
<td class="Botrule Rrule Toprule" align="left" valign="top"><span class="Bold">NDC Number</span></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">100 mcg
</td>
<td class="Rrule" align="left" valign="top">Round
</td>
<td class="Rrule" align="left" valign="top">"1"
</td>
<td class="Rrule" align="left" valign="top">Light blue
</td>
<td class="Rrule" align="left" valign="top">12
</td>
<td class="Rrule" align="left" valign="top">57881-331-12
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="left" valign="top">32
</td>
<td class="Botrule Rrule" align="left" valign="top">57881-331-32
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">200 mcg
</td>
<td class="Rrule" align="left" valign="top">Oval
</td>
<td class="Rrule" align="left" valign="top">"2"
</td>
<td class="Rrule" align="left" valign="top">Dark orange
</td>
<td class="Rrule" align="left" valign="top">12
</td>
<td class="Rrule" align="left" valign="top">57881-332-12
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="left" valign="top">32
</td>
<td class="Botrule Rrule" align="left" valign="top">57881-332-32
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">300 mcg
</td>
<td class="Rrule" align="left" valign="top">Triangle
</td>
<td class="Rrule" align="left" valign="top">"3"
</td>
<td class="Rrule" align="left" valign="top">Brown
</td>
<td class="Rrule" align="left" valign="top">12
</td>
<td class="Rrule" align="left" valign="top">57881-333-12
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="left" valign="top">32
</td>
<td class="Botrule Rrule" align="left" valign="top">57881-333-32
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">400 mcg
</td>
<td class="Rrule" align="left" valign="top">Diamond
</td>
<td class="Rrule" align="left" valign="top">"4"
</td>
<td class="Rrule" align="left" valign="top">Violet
</td>
<td class="Rrule" align="left" valign="top">12
</td>
<td class="Rrule" align="left" valign="top">57881-334-12
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"></td>
<td class="Botrule Rrule" align="left" valign="middle"></td>
<td class="Botrule Rrule" align="left" valign="middle"></td>
<td class="Botrule Rrule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="left" valign="top">32
</td>
<td class="Botrule Rrule" align="left" valign="top">57881-334-32
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">600 mcg
</td>
<td class="Botrule Rrule" align="left" valign="top">"D"
</td>
<td class="Botrule Rrule" align="left" valign="top">"6"
</td>
<td class="Botrule Rrule" align="left" valign="top">Turquoise
</td>
<td class="Botrule Rrule" align="left" valign="top">32
</td>
<td class="Botrule Rrule" align="left" valign="top">57881-336-32
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">800 mcg
</td>
<td class="Botrule Rrule" align="left" valign="top">Capsule
</td>
<td class="Botrule Rrule" align="left" valign="top">"8"
</td>
<td class="Botrule Rrule" align="left" valign="top">Indigo
</td>
<td class="Botrule Rrule" align="left" valign="top">32
</td>
<td class="Botrule Rrule" align="left" valign="top">57881-338-32
</td>
</tr>
</tbody>
</table>
<p><span class="Bold">Note: Colors and shapes are a secondary aid in product identification. Please be sure to confirm the printed dosage before dispensing.</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="s69"></a><a name="section-16"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION
</h1>
<p class="First">See FDA-approved patient labeling (<a href="#s70">Medication Guide</a>)
</p>
<p><span class="Bold">Patient/Caregiver Instructions</span></p>
<ul class="Disc">
<li>Before initiating treatment with Abstral, explain the statements below to patients and/or caregivers. Instruct patients to read the Medication Guide each time Abstral is dispensed because new information may be available.
</li>
<li>TIRF REMS Access Program<ul class="Disc">
<li>Outpatients must be enrolled in the TIRF REMS Access program before they can receive Abstral.
</li>
<li>Allow patients the opportunity to ask questions and discuss any concerns regarding Abstral or the TIRF REMS Access program.
</li>
<li>As a component of the TIRF REMS Access program, prescribers must review the contents of the Abstral Medication Guide with every patient before initiating treatment with Abstral.
</li>
<li>Advise the patient that Abstral is available only from pharmacies that are enrolled in the TIRF REMS Access program, and provide them with the telephone number and website for information on how to obtain the drug.
</li>
<li>Advise the outpatient that only enrolled health care providers may prescribe Abstral.
</li>
<li>Patient must sign the Patient-Prescriber Agreement to acknowledge that they understand the risks of Abstral.
</li>
<li>Advise patients that they may be requested to participate in a survey to evaluate the effectiveness of the TIRF REMS Access program.
</li>
</ul>
</li>
<li>Instruct patients and their caregivers that ABSTRAL contains medicine in an amount that could be fatal in children, in individuals for whom ABSTRAL is not prescribed, and in those who are not opioid tolerant.<br>Patients and their caregivers must be instructed to keep ABSTRAL, both used and unused dosage units, out of the reach of children. Patients and their caregivers must be instructed to dispose of any unneeded tablets remaining from a prescription as soon as possible [see How Supplied/Storage and Handling (<a href="#s67">16.2</a>), and Warnings and Precautions (<a href="#s19">5.2</a>).]
</li>
<li>Instruct patients and their caregivers to read the Medication Guide each time ABSTRAL is dispensed because new information may be available.
</li>
<li>Instruct patients not to take Abstral for <span class="product-label-link" type="condition" conceptid="433456" conceptname="Acute pain">acute pain</span>, <span class="product-label-link" type="condition" conceptid="439502" conceptname="Postoperative pain">postoperative pain</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> from injuries, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>, or any other short- term <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, even if they have taken other opioid analgesics for these conditions.
</li>
<li>Instruct patients on the meaning of opioid tolerance and Abstral is only to be used as a supplemental <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> medication for patients with <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> requiring regular opioids, who have developed tolerance to the opioid medication and who need additional opioid treatment of breakthrough <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> episodes.
</li>
<li>Instruct that if they are not taking an opioid medication on a regular around-the-clock basis, they must not take Abstral.
</li>
<li>You must not take more than 2 doses of ABSTRAL for each episode of breakthrough cancer <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>.
</li>
<li>You must wait two hours before treating a new episode of breakthrough <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> with ABSTRAL.
</li>
<li>Instruct patients NOT to share Abstral and that sharing Abstral with anyone else could result in the other individual's <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> due to <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>.
</li>
<li>Advise patients that Abstral contains fentanyl, which is a <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> medication similar to hydromorphone, methadone, morphine, oxycodone, and oxymorphone.
</li>
<li>Advise patients that the active ingredient in Abstral, fentanyl, is a drug that some people abuse. Abstral is to be taken only by the patient for whom it was prescribed, and protected from <span class="product-label-link" type="condition" conceptid="4087298" conceptname="Theft">theft</span> or misuse in the work or home environments.
</li>
<li>Instruct patients to talk to their doctor if breakthrough <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> is not alleviated or worsens after taking Abstral.
</li>
<li>Instruct patients to use Abstral exactly as prescribed by their doctor and not to take Abstral more often than prescribed.
</li>
<li>Caution patients that Abstral can affect a person's ability to perform activities that require a high level of attention (such as driving or using heavy machinery). Warn patients taking Abstral of these dangers and counsel accordingly.
</li>
<li>Warn patients not to combine Abstral with alcohol, sleep aids, or tranquilizers except by order of the prescribing physician, because dangerous additive effects may occur resulting in serious injury or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.
</li>
<li>Inform female patients that if they become pregnant or plan to become pregnant during treatment with Abstral to ask their doctor about the effects that Abstral (or any medicine) may have on them and their unborn child.
</li>
</ul>
<p><span class="Bold">Disposal of Unopened ABSTRAL <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Packages When No Longer Needed</span></p>
<ul class="Disc">
<li>Advise patients and their household members to dispose of any unopened packs remaining from a prescription as soon as they are no longer needed.
</li>
<li>Instruct patients that, to dispose of any unused ABSTRAL tablets, remove them from the <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> cards and flush them down the toilet. Do not dispose of the ABSTRAL <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> cards or cartons down the toilet.
</li>
<li>Detailed instructions for the proper storage, administration, disposal, and important instructions for managing an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of ABSTRAL are provided in the ABSTRAL Medication Guide. Ensure patients read this information in its entirety and give them an opportunity to have their questions answered.
</li>
<li>In the event that a caregiver requires additional assistance in disposing of excess units that remain in the home after the drug is no longer needed, instruct them to call the toll-free number for Galena Biopharma, Inc. 1-888-227-8725 or seek assistance from their local DEA office.
</li>
</ul>
</div>
<div class="Section" data-sectionCode="42231-1">
<a name="s70"></a><a name="section-17"></a><p></p>
<p class="First"><span class="Bold">Medication Guide<br></span><span class="Bold">ABSTRAL® (AB-stral) CII <br></span><span class="Bold">(fentanyl)
</span><br><span class="Bold">Sublingual tablets</span></p>
<p><span class="Bold">100 mcg, 200 mcg, 300 mcg, 400 mcg, 600 mcg, 800 mcg</span></p>
<table width="100%">
<col align="left" width="100.000%">
<tbody class="Headless"><tr class="First Last"><td class="Botrule Lrule Rrule Toprule" align="left" valign="top">
<span class="Bold">IMPORTANT:</span><br><span class="Bold">Do not use ABSTRAL unless you are regularly using another opioid <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> medicine around-the-clock for your cancer <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> and your body is used to these medicines (this means that you are opioid tolerant).</span><br><span class="Bold">Keep ABSTRAL in a safe place away from children.</span><br><span class="Bold">Get emergency medical help right away if:</span><br><ul class="Circle">
<li><span class="Bold">a child takes ABSTRAL. ABSTRAL can cause an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> in any child who takes it.</span></li>
<li><span class="Bold">an adult who has not been prescribed ABSTRAL takes it</span></li>
<li>
<span class="Bold">an adult who is not already taking opioids around-the-clock, takes ABSTRAL</span><br>
</li>
</ul>
<span class="Bold">These are medical emergencies that can cause <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. If possible, try to remove ABSTRAL from the mouth.</span>
</td></tr></tbody>
</table>
<p><span class="Bold">Read this Medication Guide completely</span> before you start taking ABSTRAL, and each time you get a new prescription. There may be new information. This Medication Guide does not take the place of talking to your healthcare provider about your medical condition or your treatment. Be sure to share this important information with members of your household and other caregivers.
</p>
<p><span class="Bold">What is the most important information I should know about ABSTRAL?</span></p>
<p><span class="Bold">ABSTRAL can cause life-threatening breathing problems which can lead to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</span></p>
<ol class="Arabic">
<li><span class="Bold"> Do not take ABSTRAL if you are not opioid tolerant.</span></li>
<li>If you stop taking your around-the-clock opioid <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> medicine for your cancer <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="Bold">you must stop</span> taking ABSTRAL. You may no longer be opioid tolerant. Talk to your healthcare provider about how to treat your <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>.
</li>
<li>
<span class="Bold"> Take ABSTRAL exactly as prescribed by your healthcare provider.</span><ul class="Circle">
<li><span class="Bold">You must not take more than 2 doses of ABSTRAL for each episode of breakthrough cancer <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>.</span></li>
<li>
<span class="Bold">You</span> must wait two hours before treating a new episode of breakthrough <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> with ABSTRAL. <span class="Bold">See the Medication Guide section "<a href="#p01">How should I take ABSTRAL?</a>" and the <a href="#e70">Patient Instructions for Use</a> at the end of this Medication Guide for detailed information about how to take ABSTRAL the right way.</span>
</li>
</ul>
</li>
<li>
<span class="Bold"> Do not switch from ABSTRAL to other medicines that contain fentanyl without talking with your healthcare provider.</span> The amount of fentanyl in a dose of ABSTRAL is not the same as the amount of fentanyl in other medicines that contain fentanyl. Your healthcare provider will prescribe a starting dose of ABSTRAL that may be different than other fentanyl containing medicines you may have been taking.
</li>
<li>
<span class="Bold"> Do not</span> take ABSTRAL for short-term <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> that you would expect to go away in a few days, such as:<ul class="Circle">
<li><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> after surgery
</li>
<li><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> or <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>
</li>
<li>dental <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>
</li>
</ul>
</li>
<li>
<span class="Bold"> Never give ABSTRAL to anyone else</span>, even if they have the same symptoms you have. It may harm them or even cause <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.  <br>ABSTRAL is a federally controlled substance (CII) because it is a strong opioid (narcotic) <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> medicine that can be misused by people who abuse prescription medicines or street drugs.<ul class="Disc">
<li>
<span class="Bold">Prevent <span class="product-label-link" type="condition" conceptid="4087298" conceptname="Theft">theft</span>, misuse or abuse. Keep ABSTRAL in a safe place</span> to protect it from being stolen. <br>ABSTRAL can be a target for people who abuse opioid (narcotic) medicines or street drugs.
</li>
<li><span class="Bold">Selling or giving away this medicine is against the law.</span></li>
</ul>
</li>
<li>ABSTRAL is available only through a program called the TIRF (<span class="Bold">T</span>ransmucosal <span class="Bold">I</span>mmediate-<span class="Bold">R</span>elease <span class="Bold">F</span>entanyl) REMS (<span class="Bold">R</span>isk <span class="Bold">E</span>valuation and <span class="Bold">M</span>itigation <span class="Bold">S</span>trategy) Access program. To receive ABSTRAL, you must:<ul class="Disc">
<li>talk to your healthcare provider
</li>
<li>understand the benefits and risks of ABSTRAL
</li>
<li>agree to all of the instructions
</li>
<li>sign the Patient-Prescriber Agreement form
</li>
</ul>
</li>
</ol>
<p><span class="Bold">What is ABSTRAL?</span></p>
<ul class="Disc">
<li>ABSTRAL is a prescription medicine that contains the medicine fentanyl.
</li>
<li>ABSTRAL is used to manage breakthrough <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in adults with cancer (18 years of age and older) who are already routinely taking other opioid <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> medicines around-the-clock for cancer <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>.
</li>
<li>ABSTRAL is started only after you have been taking other opioid <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> medicines and your body has become used to them (you are opioid tolerant). Do not use ABSTRAL if you are not opioid tolerant.
</li>
<li>ABSTRAL is a small tablet that is placed on the floor of the mouth under your tongue (sublingual) and allowed to dissolve.
</li>
<li>You must stay under your healthcare provider's care while taking ABSTRAL.
</li>
<li>ABSTRAL is only:<ul class="Circle">
<li>available through the TIRF REMS Access program
</li>
<li>given to people who are opioid tolerant
</li>
</ul>
</li>
</ul>
<p>It is not known if ABSTRAL is safe and effective in children under 18 years of age.
</p>
<p><span class="Bold">Who should not take ABSTRAL?</span></p>
<p><span class="Bold">Do not take ABSTRAL:</span></p>
<ul class="Disc">
<li><span class="Bold">if you are not opioid tolerant. Opioid tolerant means that you are already taking other opioid <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> medicines around-the- clock for your cancer <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, and your body is used to these medicines.</span></li>
<li>for short-term <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> that you would expect to go away in a few days, such as:<ul class="Circle">
<li><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> after surgery
</li>
<li><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> or <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>
</li>
<li>dental <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>
</li>
</ul>
</li>
<li>if you are allergic to any of the ingredients in ABSTRAL. See the end of this Medication Guide for a complete list of other ingredients in ABSTRAL.
</li>
</ul>
<p><span class="Bold">What should I tell my healthcare provider before taking ABSTRAL?</span></p>
<p>Before taking ABSTRAL, tell your healthcare provider if you:
</p>
<ul class="Disc">
<li>have trouble breathing or lung problems such as <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, <span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span>, or <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>
</li>
<li>have or had a <span class="product-label-link" type="condition" conceptid="375415" conceptname="Injury of head">head injury</span> or brain problem
</li>
<li>have liver or kidney problems
</li>
<li>have <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>
</li>
<li>have a slow heart rate or other heart problems
</li>
<li>have <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">low blood pressure</span>
</li>
<li>have mental health problems including <span class="product-label-link" type="condition" conceptid="4114950" conceptname="Endogenous depression">major depression</span>, <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> or <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span> (seeing or hearing things that are not there)
</li>
<li>have a past or present drinking problem (<span class="product-label-link" type="condition" conceptid="4218106" conceptname="Alcoholism">alcoholism</span>), or a family history of drinking problems
</li>
<li>have a past or present drug abuse problem or addiction problem, or a family history of a drug abuse problem or addiction problem
</li>
<li>have any other medical conditions
</li>
<li>are pregnant or plan to become pregnant. ABSTRAL may cause serious harm to your unborn baby.
</li>
<li>are breastfeeding or plan to breastfeed. ABSTRAL can pass into your breast milk. It can cause serious harm to your baby. You should not use ABSTRAL while breastfeeding.
</li>
</ul>
<p><span class="Bold">Tell your healthcare provider about all the medicines you take</span>, including prescription and non-prescription medicines, vitamins, and herbal supplements. Some medicines may cause serious or life-threatening side effects when taken with ABSTRAL. Sometimes, the doses of certain medicines and ABSTRAL may need to be changed if used together.
</p>
<ul class="Disc">
<li>
<span class="Bold">Do not take any medicine while using ABSTRAL until you have talked to your healthcare provider.</span> Your healthcare provider will tell you if it is safe to take other medicines while you are using ABSTRAL.
</li>
<li>Be very careful about taking other medicines that may make you <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepy</span>, such as other <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> medicines, anti-depressants, sleeping pills, anti-<span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span> medicines, antihistamines, or tranquilizers.
</li>
</ul>
<p>Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.
</p>
<p><a name="p01"></a><span class="Bold">How should I take ABSTRAL?</span></p>
<p><span class="Bold">Before you can begin to take ABSTRAL:</span></p>
<ul class="Disc">
<li>Your healthcare provider will explain the TIRF REMS Access program to you.
</li>
<li>You will sign the TIRF REMS Access program Patient-Prescriber Agreement form.
</li>
<li>ABSTRAL is only available at pharmacies that are part of the TIRF REMS Access program. Your healthcare provider will let you know the pharmacy closest to your home where you can have your ABSTRAL prescription filled.
</li>
</ul>
<p><span class="Bold">Taking ABSTRAL:</span></p>
<ul class="Disc">
<li><span class="Bold">Take ABSTRAL exactly as prescribed. Do not take ABSTRAL more often than prescribed.</span></li>
<li>
<span class="Bold">If you notice that your tablets are a different shape or color,</span> be sure to check with your pharmacist to make sure you have the right strength of medicine.
</li>
<li>
<span class="Bold">Do not</span> suck, chew or swallow the tablet.
</li>
<li><span class="Bold">See the detailed <a href="#e70">Patient Instructions for Use</a> at the end of this Medication Guide for information about how to take ABSTRAL the right way.</span></li>
<li>Your healthcare provider will change the dose until you and your healthcare provider find the right dose for you.
</li>
<li>You must not use more than 2 doses of ABSTRAL for each episode of breakthrough cancer <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>:<ul class="Circle">
<li>Take 1 dose for an episode of breakthrough cancer <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>. o If your breakthrough <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> does not get better within 30 minutes after taking the first dose of
</li>
<li>ABSTRAL, you can take 1 more dose of ABSTRAL as instructed by your healthcare provider.
</li>
<li>If your breakthrough <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> does not get better after the second dose of ABSTRAL, call your healthcare provider for instructions. <span class="Bold">Do not take another dose of ABSTRAL at this time.</span>
</li>
</ul>
</li>
<li>Wait at least 2 hours before treating a new episode of breakthrough cancer <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> with ABSTRAL:<ul class="Circle">
<li>If you only need to take 1 dose of ABSTRAL for an episode of breakthrough <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, you must wait 2 hours from the time of that dose to take a dose of ABSTRAL for a <span class="Bold">new</span> episode of breakthrough <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>
</li>
<li>If you need to take 2 doses of ABSTRAL for an episode of breakthrough <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, you must wait 2 hours after the second dose to take a dose of ABSTRAL for a <span class="Bold">new</span> episode of breakthrough <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>.
</li>
</ul>
</li>
<li>It is important for you to keep taking your around-the-clock opioid <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> medicine while taking ABSTRAL.
</li>
<li>Talk to your healthcare provider if your dose of ABSTRAL does not relieve your breakthrough cancer <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>. Your healthcare provider will decide if your dose of ABSTRAL needs to be changed.
</li>
<li>Talk to your healthcare provider if you have more than 4 episodes of breakthrough cancer <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> per day. The dose of your around- the-clock opioid <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> medicine may need to be adjusted.
</li>
<li>If you take too much ABSTRAL or <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, you or your caregiver should call for emergency medical help or have someone take you to the nearest hospital emergency room right away.
</li>
</ul>
<p><span class="Bold">What should I avoid while taking ABSTRAL?</span></p>
<ul class="Disc">
<li>
<span class="Bold">Do not drive, operate heavy machinery, or do other dangerous activities</span> until you know how ABSTRAL affects you. ABSTRAL can make you <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepy</span>. Ask your healthcare provider when it is okay to do these activities.
</li>
<li>
<span class="Bold">Do not drink alcohol while using ABSTRAL.</span> It can increase your chance of getting dangerous side effects.
</li>
</ul>
<p><span class="Bold">What are the possible side effects of ABSTRAL?</span></p>
<p><span class="Bold">ABSTRAL can cause serious side effects, including:</span></p>
<ol class="Arabic">
<li>
<span class="Bold"> Breathing problems that can become life-threatening.</span> See "What is the most important information I should know about ABSTRAL?"<ul class="Disc"><li>Call your healthcare provider or get emergency medical help right away if you:<ul class="Circle">
<li>have trouble breathing
</li>
<li>have <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> with slowed breathing
</li>
<li>have <span class="product-label-link" type="condition" conceptid="4302536" conceptname="Shallow breathing">shallow breathing</span> (little chest movement with breathing)
</li>
<li>feel <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">faint</span>, very dizzy, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confused</span>, or have other unusual symptoms
</li>
</ul>
<p class="First">These symptoms can be a sign that you have taken too much ABSTRAL or the dose is too high for you. <span class="Bold">These symptoms may lead to serious problems or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> if not treated right away. If you have any of these symptoms, do not take any more ABSTRAL until you have talked to your healthcare provider.</span></p>
</li></ul>
</li>
<li>
<span class="Bold"> Decreased blood pressure.</span> This can make you feel dizzy or lightheaded if you get up too fast from sitting or lying down.
</li>
<li>
<span class="Bold"> Physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>. Do not stop taking ABSTRAL or any other opioid, without talking to your healthcare provider.</span> You could become sick with uncomfortable withdrawal symptoms because your body has become used to these medicines. Physical dependency is not the same as <span class="product-label-link" type="condition" conceptid="440069" conceptname="Drug dependence">drug addiction</span>.
</li>
<li>
<span class="Bold"> A chance of abuse or addiction.</span> This chance is higher if you are or have ever been addicted to or abused other medicines, street drugs, or alcohol, or if you have a history of mental health problems.
</li>
</ol>
<p>The most common side effects of ABSTRAL are:
</p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepiness</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>
</li>
</ul>
<p><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span> (not often enough or hard bowel movements) is a very common side effect of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> medicines (opioids) including ABSTRAL and is unlikely to go away without treatment. Talk to your healthcare provider about dietary changes, and the use of laxatives (medicines to treat <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>) and stool softeners to prevent or treat <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> while taking ABSTRAL.
</p>
<p>Tell your healthcare provider if you have any side effect that bothers you or that does not go away.
</p>
<p>These are not all the possible side effects of ABSTRAL. For more information, ask your healthcare provider or pharmacist.
</p>
<p>Call your doctor for medical advice about your side effects. You may report side effects to FDA at 1-800FDA-1088.
</p>
<p><span class="Bold">How should I store ABSTRAL?</span></p>
<ul class="Disc">
<li>
<span class="Bold">Always keep ABSTRAL in a safe place away from children and from anyone for whom it has not been prescribed.</span> Protect ABSTRAL from <span class="product-label-link" type="condition" conceptid="4087298" conceptname="Theft">theft</span>.
</li>
<li>Store ABSTRAL at room temperature, 59°F to 86°F (15°C to 30°C) until ready to use.
</li>
<li>Keep ABSTRAL in the original <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> unit. Do not remove ABSTRAL tablets from their <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> packaging for storage in a temporary container, such as a pillbox.
</li>
</ul>
<p><span class="Bold">How should I dispose of unopened ABSTRAL tablets when they are no longer needed?</span></p>
<ul class="Disc">
<li>Dispose of any unopened ABSTRAL units remaining from a prescription as soon as you no longer need them:<ul class="Circle"><li>remove the tablets from the <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> cards and flush them down the toilet.
</li></ul>
</li>
<li>Do not flush the ABSTRAL <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> cards, units or cartons down the toilet.
</li>
<li>If you need help with disposal of ABSTRAL, call Galena Biopharma, Inc.., at 1-888-227-8725 or call your local Drug Enforcement Agency (DEA) office.
</li>
</ul>
<p><span class="Bold">General information about ABSTRAL</span></p>
<p>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. <span class="Bold">Use ABSTRAL only for the purpose for which it was prescribed. Do not give ABSTRAL to other people, even if they have the same symptoms you have.</span> ABSTRAL can harm other people and even cause <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Sharing ABSTRAL is against the law.
</p>
<p>This Medication Guide summarizes the most important information about ABSTRAL. If you would like more information, talk with your healthcare provider or pharmacist. You can ask your pharmacist or healthcare provider for information about ABSTRAL that is written for healthcare professionals.
</p>
<p>For more information about the TIRF REMS Access program, go to <span class="Underline">www.TIRFREMSAccess.com</span> or call 1866-822-1483.
</p>
<p><span class="Bold">What are the ingredients in ABSTRAL?</span></p>
<p>Active Ingredient: fentanyl citrate
</p>
<p>Inactive Ingredients: croscarmellose sodium, magnesium stearate, mannitol, and silicified microcrystalline cellulose.
</p>
</div>
<div class="Section" data-sectionCode="59845-8">
<a name="e70"></a><a name="section-18"></a><p></p>
<p class="First"><span class="Bold">Patient Instructions for Use</span></p>
<p>Before you take ABSTRAL, it is important that you read the Medication Guide and these Patient Instructions for Use. Be sure that you read, understand, and follow these Patient Instructions for Use so that you take ABSTRAL the right way. Ask your healthcare provider or pharmacist if you have questions about the right way to take ABSTRAL.
</p>
<p><span class="Bold">When you get an episode of breakthrough <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, take the dose prescribed by your healthcare provider as follows:</span></p>
<ul class="Disc">
<li>If your mouth is dry, take a sip of water to moisten it. Spit out or swallow the water. Dry your hands if they are wet before you handle ABSTRAL tablets.
</li>
<li>ABSTRAL comes in a <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> card with 4 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> units. Each <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> unit contains an ABSTRAL tablet. It is important that the tablet stays sealed in the <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> unit until you are ready to use it.
</li>
<li>When you are ready to take an ABSTRAL tablet, pull apart 1 of the <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> units from the <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> card by tearing along the dotted lines (perforations) until it is fully separated. (See <a href="#f05">Figures 1 and 2</a>)<p class="First"><a name="f05"></a><img alt="Figures 1 and 2
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=f969e2bc-6297-4e29-89d3-a3685a2c7c6b&amp;name=abs02-0001-05.jpg"></p>
</li>
<li>When the <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> unit is fully separated, peel back the foil starting at the unsealed area where indicated. Gently remove the tablet. <span class="Bold">Do not</span> try to push ABSTRAL tablets through the foil. This will damage the tablet. (See <a href="#f06">Figures 3 and 4</a>)<p class="First"><a name="f06"></a><img alt="Figures 3 and 4
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=f969e2bc-6297-4e29-89d3-a3685a2c7c6b&amp;name=abs02-0001-06.jpg"></p>
</li>
<li>As soon as you remove the ABSTRAL tablet from the <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> unit:<ul class="Circle">
<li>place it on the floor of your mouth, under your tongue, as far back as you can (See <a href="#f07">Figures 5, 6, and 7</a>).<p class="First"><a name="f07"></a><img alt="Figures 5, 6, and 7
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=f969e2bc-6297-4e29-89d3-a3685a2c7c6b&amp;name=abs02-0001-07.jpg"></p>
</li>
<li>If more than 1 tablet is required, spread them around the floor of your mouth under your tongue.
</li>
<li>Let the tablet dissolve completely.
</li>
<li>ABSTRAL dissolves under your tongue and will be absorbed by your body to help provide relief for your breakthrough cancer <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>.
</li>
<li><span class="Bold">Do not suck, chew or swallow the tablet.</span></li>
<li>You should not drink or eat anything until the tablet has completely dissolved under your tongue and you can no longer feel it in your mouth.
</li>
</ul>
</li>
</ul>
<p>Manufactured by: <br>Pharmaceutics International, Inc. <br>Hunt Valley, MD 21031
</p>
<p>Manufactured for: <br>Galena Biopharma, Inc. <br>Portland, OR 97239
</p>
<p>Issued:  November 2014
</p>
<p>This Medication Guide has been approved by the U.S. Food and Drug Administration. Copyright © 2013, Galena Biopharma, Inc. All rights reserved.
</p>
<p>ABSTRAL and Galena Biopharma are trademarks owned by the Galena Biopharma, Inc.
</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s71"></a><a name="section-19"></a><p></p>
<p class="First"><span class="Bold">Principal Display Panel – 100 mcg Carton Label</span></p>
<p><span class="Bold">ABSTRAL</span><span class="Bold"><span class="Sup">®</span></span><span class="Bold">CII</span></p>
<p><span class="Bold">(fentanyl) sublingual tablets</span></p>
<p><span class="Bold">NDC 57881-331-32</span></p>
<p><span class="Bold">Rx only</span></p>
<p><span class="Bold">equivalent to 100 mcg fentanyl base</span></p>
<p><span class="Bold">32 Sublingual Tablets</span></p>
<p>(4 tablets x 8 cards)
</p>
<p>Mfd. by: Pharmaceutics International, Inc., Hunt Valley, MD 21031
</p>
<p>Mfd. for: Galena Biopharma Inc., Suite 208, 310 N. State St., Lake Oswego, OR 97034
</p>
<p>For questions about ABSTRAL<span class="Sup">®</span> call: 1-888-ABSTRAL.
</p>
<div class="Figure">
<a name="f08"></a><img alt="Principal Display Panel – 100 mcg Carton Label
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=f969e2bc-6297-4e29-89d3-a3685a2c7c6b&amp;name=abs02-0001-08.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s72"></a><a name="section-20"></a><p></p>
<p class="First"><span class="Bold">Principal Display Panel – 200 mcg Carton Label</span></p>
<p><span class="Bold">ABSTRAL</span><span class="Bold"><span class="Sup">®</span></span><span class="Bold">CII</span></p>
<p><span class="Bold">(fentanyl) sublingual tablets</span></p>
<p><span class="Bold">NDC 57881-332-32</span></p>
<p><span class="Bold">Rx only</span></p>
<p><span class="Bold">equivalent to 200 mcg fentanyl base</span></p>
<p><span class="Bold">32 Sublingual Tablets</span></p>
<p>(4 tablets x 8 cards)
</p>
<p>Mfd. by: Pharmaceutics International, Inc., Hunt Valley, MD 21031
</p>
<p>Mfd. for: Galena Biopharma Inc., Suite 208, 310 N. State St., Lake Oswego, OR 97034
</p>
<p>For questions about ABSTRAL<span class="Sup">®</span> call: 1-888-ABSTRAL.
</p>
<div class="Figure">
<a name="f09"></a><img alt="Principal Display Panel – 200 mcg Carton Label
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=f969e2bc-6297-4e29-89d3-a3685a2c7c6b&amp;name=abs02-0001-09.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s73"></a><a name="section-21"></a><p></p>
<p class="First"><span class="Bold">Principal Display Panel – 300 mcg Carton Label</span></p>
<p><span class="Bold">ABSTRAL</span><span class="Bold"><span class="Sup">®</span></span><span class="Bold">CII</span></p>
<p><span class="Bold">(fentanyl) sublingual tablets</span></p>
<p><span class="Bold">NDC 57881-333-32</span></p>
<p><span class="Bold">Rx only</span></p>
<p><span class="Bold">equivalent to 300 mcg fentanyl base</span></p>
<p><span class="Bold">32 Sublingual Tablets</span></p>
<p>(4 tablets x 8 cards)
</p>
<p>Mfd. by: Pharmaceutics International, Inc., Hunt Valley, MD 21031
</p>
<p>Mfd. for: Galena Biopharma Inc., Suite 208, 310 N. State St., Lake Oswego, OR 97034
</p>
<p>For questions about ABSTRAL<span class="Sup">®</span> call: 1-888-ABSTRAL.
</p>
<div class="Figure">
<a name="f10"></a><img alt="Principal Display Panel – 300 mcg Carton Label
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=f969e2bc-6297-4e29-89d3-a3685a2c7c6b&amp;name=abs02-0001-10.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s74"></a><a name="section-22"></a><p></p>
<p class="First"><span class="Bold">Principal Display Panel – 400 mcg Carton Label</span></p>
<p><span class="Bold">ABSTRAL</span><span class="Bold"><span class="Sup">®</span></span><span class="Bold">CII</span></p>
<p><span class="Bold">(fentanyl) sublingual tablets</span></p>
<p><span class="Bold">NDC 57881-334-32</span></p>
<p><span class="Bold">Rx only</span></p>
<p><span class="Bold">equivalent to 400 mcg fentanyl base</span></p>
<p><span class="Bold">32 Sublingual Tablets</span></p>
<p>(4 tablets x 8 cards)
</p>
<p>Mfd. by: Pharmaceutics International, Inc., Hunt Valley, MD 21031
</p>
<p>Mfd. for: Galena Biopharma Inc., Suite 208, 310 N. State St., Lake Oswego, OR 97034
</p>
<p>For questions about ABSTRAL<span class="Sup">®</span> call: 1-888-ABSTRAL.
</p>
<div class="Figure">
<a name="f11"></a><img alt="Principal Display Panel – 400 mcg Carton Label
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=f969e2bc-6297-4e29-89d3-a3685a2c7c6b&amp;name=abs02-0001-11.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s75"></a><a name="section-23"></a><p></p>
<p class="First"><span class="Bold">Principal Display Panel – 600 mcg Carton Label</span></p>
<p><span class="Bold">ABSTRAL</span><span class="Bold"><span class="Sup">®</span></span><span class="Bold">CII</span></p>
<p><span class="Bold">(fentanyl) sublingual tablets</span></p>
<p><span class="Bold">NDC 57881-336-32</span></p>
<p><span class="Bold">Rx only</span></p>
<p><span class="Bold">equivalent to 600 mcg fentanyl base</span></p>
<p><span class="Bold">32 Sublingual Tablets</span></p>
<p>(4 tablets x 8 cards)
</p>
<p>Mfd. by: Pharmaceutics International, Inc., Hunt Valley, MD 21031
</p>
<p>Mfd. for: Galena Biopharma Inc., Suite 208, 310 N. State St., Lake Oswego, OR 97034
</p>
<p>For questions about ABSTRAL<span class="Sup">®</span> call: 1-888-ABSTRAL.
</p>
<div class="Figure">
<a name="f12"></a><img alt="Principal Display Panel – 600 mcg Carton Label
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=f969e2bc-6297-4e29-89d3-a3685a2c7c6b&amp;name=abs02-0001-12.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s76"></a><a name="section-24"></a><p></p>
<p class="First"><span class="Bold">Principal Display Panel – 800 mcg Carton Label</span></p>
<p><span class="Bold">ABSTRAL</span><span class="Bold"><span class="Sup">®</span></span><span class="Bold">CII</span></p>
<p><span class="Bold">(fentanyl) sublingual tablets</span></p>
<p><span class="Bold">NDC 57881-338-32</span></p>
<p><span class="Bold">Rx only</span></p>
<p><span class="Bold">equivalent to 800 mcg fentanyl base</span></p>
<p><span class="Bold">32 Sublingual Tablets</span></p>
<p>(4 tablets x 8 cards)
</p>
<p>Mfd. by: Pharmaceutics International, Inc., Hunt Valley, MD 21031
</p>
<p>Mfd. for: Galena Biopharma Inc., Suite 208, 310 N. State St., Lake Oswego, OR 97034
</p>
<p>For questions about ABSTRAL<span class="Sup">®</span> call: 1-888-ABSTRAL.
</p>
<div class="Figure">
<a name="f13"></a><img alt="Principal Display Panel – 800 mcg Carton Label
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=f969e2bc-6297-4e29-89d3-a3685a2c7c6b&amp;name=abs02-0001-13.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ABSTRAL 		
					</strong><br><span class="contentTableReg">fentanyl citrate tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:57881-331</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">SUBLINGUAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">CII    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>fentanyl citrate</strong> (fentanyl) </td>
<td class="formItem">fentanyl</td>
<td class="formItem">100 ug</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>croscarmellose sodium</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>mannitol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>cellulose, microcrystalline</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">BLUE (light blue) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND (ROUND) </td>
<td class="formLabel">Size</td>
<td class="formItem">10mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">1
</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:57881-331-32</td>
<td class="formItem">8  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:57881-331-04</td>
<td class="formItem">4  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022510</td>
<td class="formItem">08/08/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ABSTRAL 		
					</strong><br><span class="contentTableReg">fentanyl citrate tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:57881-332</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">SUBLINGUAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">CII    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>fentanyl citrate</strong> (fentanyl) </td>
<td class="formItem">fentanyl</td>
<td class="formItem">200 ug</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>croscarmellose sodium</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>mannitol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>cellulose, microcrystalline</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">ORANGE (dark orange) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (OVAL) </td>
<td class="formLabel">Size</td>
<td class="formItem">10mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">2
</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:57881-332-32</td>
<td class="formItem">8  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:57881-332-04</td>
<td class="formItem">4  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022510</td>
<td class="formItem">08/08/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ABSTRAL 		
					</strong><br><span class="contentTableReg">fentanyl citrate tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:57881-333</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">SUBLINGUAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">CII    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>fentanyl citrate</strong> (fentanyl) </td>
<td class="formItem">fentanyl</td>
<td class="formItem">300 ug</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>croscarmellose sodium</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>mannitol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>cellulose, microcrystalline</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">BROWN (brown) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">TRIANGLE (TRIANGLE) </td>
<td class="formLabel">Size</td>
<td class="formItem">10mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">3
</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:57881-333-32</td>
<td class="formItem">8  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:57881-333-04</td>
<td class="formItem">4  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022510</td>
<td class="formItem">08/08/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ABSTRAL 		
					</strong><br><span class="contentTableReg">fentanyl citrate tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:57881-334</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">SUBLINGUAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">CII    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>fentanyl citrate</strong> (fentanyl) </td>
<td class="formItem">fentanyl</td>
<td class="formItem">400 ug</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>croscarmellose sodium</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>mannitol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>cellulose, microcrystalline</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">PURPLE (violet) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">DIAMOND (DIAMOND) </td>
<td class="formLabel">Size</td>
<td class="formItem">10mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">4
</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:57881-334-32</td>
<td class="formItem">8  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:57881-334-04</td>
<td class="formItem">4  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022510</td>
<td class="formItem">08/08/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ABSTRAL 		
					</strong><br><span class="contentTableReg">fentanyl citrate tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:57881-336</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">SUBLINGUAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">CII    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>fentanyl citrate</strong> (fentanyl) </td>
<td class="formItem">fentanyl</td>
<td class="formItem">600 ug</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>croscarmellose sodium</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>mannitol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>cellulose, microcrystalline</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">TURQUOISE (turquoise) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">SEMI-CIRCLE (D-SHAPE) </td>
<td class="formLabel">Size</td>
<td class="formItem">10mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">6
</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:57881-336-32</td>
<td class="formItem">8  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:57881-336-04</td>
<td class="formItem">4  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022510</td>
<td class="formItem">08/08/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ABSTRAL 		
					</strong><br><span class="contentTableReg">fentanyl citrate tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:57881-338</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">SUBLINGUAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">CII    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>fentanyl citrate</strong> (fentanyl) </td>
<td class="formItem">fentanyl</td>
<td class="formItem">800 ug</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>croscarmellose sodium</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>mannitol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>cellulose, microcrystalline</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">BLUE (indigo) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE (CAPSULE) </td>
<td class="formLabel">Size</td>
<td class="formItem">10mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">8
</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:57881-338-32</td>
<td class="formItem">8  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:57881-338-04</td>
<td class="formItem">4  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022510</td>
<td class="formItem">08/08/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Galena Biopharma, Inc.
							(044320456)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Pharmaceutics International, Inc.</td>
<td class="formItem"></td>
<td class="formItem">878265586</td>
<td class="formItem">MANUFACTURE(57881-331, 57881-332, 57881-333, 57881-334, 57881-336, 57881-338)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 11/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>621fd88b-b921-47a2-94bd-a778d6005353</div>
<div>Set id: f969e2bc-6297-4e29-89d3-a3685a2c7c6b</div>
<div>Version: 2</div>
<div>Effective Time: 20141130</div>
</div>
</div> <div class="DistributorName">Galena Biopharma, Inc.</div></p>
</body></html>
